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ABSTRACT 
Mary Jeannette Sperlazza: Structure and Function Studies of Methyl-CpG Binding 
Domain Proteins and Their Complexes 
(Under the direction of David C Williams Jr) 
 
DNA methylation is an epigenetic mechanism of transcriptional silencing of 
increasing interest for treating human disease. Methyl-CpG binding domain (MBD) 
proteins recognize 5-methylcytosines (mC) primarily in symmetrical CpG (mCG) 
dinucleotides. Seven proteins comprise the MBD family, MBD1-6 and MeCP2. MeCP2 
is primarily expressed in the brain and plays a critical role in neuron maturation, as 
mutations disrupting its function account for up to 80% of Rett Syndrome cases. 
MBD2/3 associates with the nucleosome remodeling and deacetylase complex (NuRD) 
and modulates gene expression through alteration of the chromatin architecture 
surrounding the mC mark. In these studies, we examine the behavior of the MBDs of 
MeCP2 and MBD2, in addition to further characterizing the protein-protein interactions 
between subunits of NuRD.         
Recent work suggests the primary effects of MeCP2 on gene expression in the 
developing mammalian brain are mediated by binding asymmetrically methylated and 
hydroxymethylated CpA (h/mCA) dinucleotides. This work establishes that the MeCP2 
MBD binds mCA with high affinity in a strand specific and orientation dependent 
manner. This preference is specific to MeCP2, as the MBD2 MBD does not show high 
affinity or methyl-specific binding to mCA. Introduction of the Rett Syndrome-associated 
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mutations T158M, R106W and P101S destabilized the MeCP2 MBD and lessened 
recognition of mCG and mCA equally. Finally, hydroxymethylation of a high affinity mCA 
site did not dramatically change binding properties, however hemi-hydroxylation of the 
same cytosine in mCG significantly decreased affinity. We suggest a model for MeCP2 
recognition of mCA and for hydroxymethylation as an epigenetic switch to redistribute 
MeCP2 among mCG and mCA loci. 
 Blocking recruitment of NuRD by MBD2 restores expression of developmentally 
silenced fetal hemoglobin and aberrantly silenced tumor suppressor genes. Additionally, 
knockdown of the NuRD helicase, CHD4, results in cancer cells growth arrest and 
increased sensitivity to DNA damage. Therefore, targeting MBD2-NuRD presents a 
promising avenue for treating β-hemoglobinopathies and cancer. Towards 
understanding the recruitment of the NuRD components to the complex, this study 
characterizes the GATA-like zinc-finger domains of the NuRD components GATAD2A 
and MTA2. We propose a model of NuRD in which MTA2 binds DNA and GATAD2A 
serves to bridge MBD2 and CHD4.  
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CHAPTER 1: INTRODUCTION TO DNA METHYLATION AND METHYL-CpG 
BINDING DOMAIN PROTEINS 
 
DNA Methylation and Epigenetics 
The regulation of gene expression is a highly dynamic process, simultaneously 
choreographed by an array of signals from transcription factor activation to chromatin 
remodeling. Epigenetic regulation of transcription enables responsive changes in 
genetic output relative to environmental conditions. In the development of complex 
organisms, cells must coordinate correctly timed events and signaling processes to 
guide cell differentiation. During organ formation, fluctuations in the patterns of genes 
expressed gradually define the profile that enables the specific functions of each tissue. 
Even into late fetal development and the early stages of life, transcription is modulated 
over time to transition from the developmental to the adult proteome. This shift is often 
accomplished by employing DNA methylation, a heritable epigenetic modification of 
cytosine bases that directs long-term gene silencing.  
In humans, DNA is methylated by DNA methyltransferases (DNMTs) at the 5C 
position of cytosine (mC), primarily in cytosine-guanine (CpG) dinucleotides. CpG 
dinucleotides are commonly clustered into “CpG islands” within the 5’ regulatory regions 
of about 60% of transcribed gene promoters. 1,2 In healthy somatic cells, the majority of 
CpG islands are unmodified 3, with the approximately 4% of all cytosines in the human 
genome being methylated in regions of non-coding DNA, repetitive elements, gene 
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imprinting and X-chromosome inactivation 4,5. In addition to disrupting transcription 
factor binding to target sequences, cytosine methylation creates docking sites for 
methyl-binding proteins and their associated co-repressor complexes to prevent 
transcription activation 4. 
Chromatin Structure and Transcription Regulation 
Eukaryotic organisms organized genomic DNA into a dynamic higher ordered 
structure called chromatin. Chromatin is comprised of repeating units of nucleosomes, 
~147 base pairs chromosomal DNA wrapped around histone protein octamers of the 
histone proteins H2A, H2B, H3, and H4 6–8. Nucleosomes assemble in an array 
connected by linker regions of DNA which are bound by the histone protein H1 to form 
chromatosomes illustrated in Figure 1.19,10. The 1.8 meters of DNA in a cell can then be 
wound into higher order structures and packaged into a single cell nucleus. The linker 
DNA between nucleosomes varies in length and the spacing of nucleosomes regulates 
local genome access to the transcription machinery. The presence of nucleosomes 
impedes transcription factor binding and RNA Polymerase II transcription initiation 11. 
Therefore, genomic areas of active transcription tend to be less densely populated with 
nucleosomes, known as euchromatin, while in silenced regions nucleosomes spacing is 
more compact, known as heterochromatin 3.  
The structure of chromatic regions is influenced by histone protein post-
translational modifications and nucleosome repositioning activity of chromatin 
remodeling enzymes. The histone octamer core of nucleosomes possesses about 80 
sites for several different covalent post-translational modifications (PTMs), such as 
methylation, acetylation, phosphorylation, and ubiquitination, illustrated in Figure 1.2 12. 
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PTMs constitute the “histone code”, a highly dynamic pattern of epigenetic marks that 
can be modified by enzymes depositing (“writers”) or removing (“erasers”) PTMs. The 
presence or absence of a PTM can be recognized by “reader” proteins that in turn 
signal for the activation or repression of transcription 13. For example, histone 
acetylation is heavily associated with transcriptional activation and, conversely, 
deacetylation correlates with the repression of gene expression 14. Histone “reader” 
proteins often recruit ATP-dependent chromatin remodeling enzymes, which assemble, 
slide, or eject nucleosomes to compact or loosen chromatin structure 15. The co-
repressor complexes associated with methyl-DNA binding proteins often contain histone 
reading domains, a histone deacetylase enzyme, and a chromatin remodeling ATP-ase 
to create and maintain heterochromatin 16. 
Methyl-CpG Binding Domain Protein Family 
In humans, DNA methylation signals are read by members of the methyl-CpG 
binding domain (MBD) family of proteins encompassing MeCP2 and MBD1 through 
MBD6 16. The protein family members contain a homologous MBD domain of ~70 amino 
acids with the selectivity for methylated CpG dinucleotides (mCG) varying from a high 
preference (MBD1, MBD2, MeCP2) or minimal preference (MBD3, MBD4) 17 to none 
(MBD5, MBD6) 18. The available crystal and solution structures of MBD proteins bound 
to DNA reveal mCG motifs are similarly recognized across the family (PDBs: 1IG4, 
3C2I, 2KY8, 3VXX, 2MOE), employing two conserved arginines and a tyrosine in 
methylation-specific binding  19–23. However, the domain architecture outside of the MBD 
and the associated complexes vary among family members (except MBD2/MBD3), 
contributing to differences in the preferred sequence context of the mC motif and their 
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ability to perform distinct functions (Table 1.1) 24. MBD1, MBD2, and MeCP2 each 
contain an additional transcriptional repression domain that is thought to mediate 
interaction with co-repressor complexes, which include histone deacetylases and 
chromatin remodeling enzymes, to translate the methylation signal into a change in 
local genome structure, illustrated in Figure 1.3 16. Additionally, MeCP2 is found at 
levels rivaling histone H1 and has been suggested to compact higher-order chromatin 
structure by competing for binding sites of the linker histone in chromatosomes 25. 
MBD Proteins and Human Disease 
Chromatin remodeling is a dynamic and reversible means of controlling cellular 
genetic output, therefore the proteins responsible for modulating nucleosome 
positioning are appealing therapeutic targets 26–29. Aberrant nucleosome organization 
can severely disrupt gene expression, DNA repair and cellular differentiation, and is 
associated with disorders including schizophrenia 30, cardiovascular disease 31, 
intellectual disability 30,32 and cancer 33–35. The role of DNA methylation in disease has 
been most extensively studied in cancer, beginning in the early 1980’s. Tumor 
methylome profiles are globally hypomethylated, possibly to relax the repression of 
imprinted, viral and repetitive gene elements, while CpG islands within the promoters of 
tumor suppressor genes often locally hypermethylated, when compared to healthy 
tissue. This abnormal hypermethylation correlates with transcriptional silencing, and 
thereby effective inactivation, of tumor suppressor genes 36.  
Consequently, the first epigenetic chemotherapies were cytosine analogs, 5-
azacitidine, and decitabine, modified at the 5th carbon position to prevent methylation 
when incorporated into genomic DNA and inhibit DNMTs, to restore the expression of 
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tumor suppressors 37,38. Clinically these compounds are approved for use in 
myelodysplastic syndrome and leukemia, however, their effectiveness in is limited by 
systemic toxicity, including myelosuppression 39. Treating cancer continues to be the 
focus of the epigenetic-based drug discovery and the majority on the market (and in 
development) target the “writers” and “erasers” of DNA methylation and the histone 
code (Table 1.2) 40. Epigenetic “readers” and their associated chromatin remodeling 
enzymes, therefore, represent a powerful class of novel drug targets that have yet to be 
thoroughly explored. Mutations, downregulation, and overexpression of MBD family 
proteins have been associated with malignancies of the breast, uterus, lung, brain and 
gastrointestinal system 16. MeCP2 and MBD2 have garnered specific interest as targets 
in cancer and beyond for their roles in cell differentiation, growth, and maturation. 
MeCP2 Association with Neurological Disorders 
 Methyl-CpG binding protein 2 (MeCP2) is most abundantly expressed in the 
brain and is critical for neural development. It is encoded on the long arm of the X-
chromosome, and perturbations of protein expression levels or sequence are 
associated with schizophrenia, Prader-Willi syndrome, Angleman syndrome and, most 
notably, Rett syndrome 16. Missense and frameshift mutations throughout MeCP2 occur 
in up to 80% of Rett syndrome cases, a disorder that affects about 1 in 10,000 females 
characterized by stagnated, sometimes regressive neurological development at 6-18 
months of age 41–43. The timing of the onset of Rett syndrome symptoms correlates with 
the period during which MeCP2 expression levels rise and mCG motifs accumulate in 
brain cells 44–46. Recent advancements in base-resolution methylome sequencing have 
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revealed significant levels of non-CpG methylation also accumulate in developing brain 
cells and additional specificity for mC(A, T, or G) have been described for MeCP2 47. 
Transcription is globally affected by MeCP2 dysfunction, in addition to 
misregulation of specific genes involved in differentiation, metabolism and neuronal 
growth, including BDNF, GAMT, FXYD1, and DLX5 48–50. Rett syndrome affects 
cognitive, sensory, emotional, motor, and autonomic functions, including autism-like 
features in learning, speech and social deficits, as well as seizures, digestive problems, 
and irregular breathing patterns 41. Symptoms vary significantly from patient to patient, 
however, some identified MeCP2 mutations can be predictive of the severity of disability 
51,52. No drugs have been approved to treat the underlying defect in MeCP2 or 
manipulate downstream effectors and clinical trials testing methods to minimize 
symptoms have not yet yielded significant results 53.  
About 20% of Rett syndrome-associated mutations in MeCP2 occur in the MBD 
domain 54. Investigations of missense mutations in the MBD have revealed destabilizing 
effects on protein structure, reductions in methylated DNA binding selectivity and 
impaired transcriptional repression activity 54–60. Neurological symptoms in immature 
and mature conditional MeCP2 knock-out mice can be reversed upon re-activation of 
wild-type protein expression 61, therefore strategies to re-stabilize the MBD domain and 
restore methylated DNA binding function hold promise for treating this population of Rett 
Syndrome patients.  
MBD2 Developmental Silencing of Globin Genes 
 Hemoglobinopathies are the world’s most common diseases caused by a single 
gene defect. The genes of the human β-globin locus are encoded in the order which 
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they are expressed during development: 5′- ε - γ - δ- β 3′. Embryonic ε-globin 
expression by the yolk sac is silenced as γ-globin expression rises in the fetal liver, 
which is in turn silenced during post-natal development as hematopoiesis shifts to the 
bone-marrow, activating adult β-globin expression, illustrated in Figure 1 62. The switch 
from fetal to adult hemoglobin expression is not irreversible, therefore sickle cell anemia 
and β-thalassemia patients suffering from mutations in the β-globin gene can receive 
therapeutic benefit from the induction of γ-globin production. Hydroxyurea is currently 
used to treat sickle cell anemia through increasing γ-globin expression, however, its 
efficacy varies between individuals and it is not effective for treating β-thalassemia 63. 
Therefore, epigenetic mechanisms of globin gene silencing have become of interest as 
a novel therapeutic approach. 
 DNA methylation and histone modifications both play roles in developmental 
globin gene silencing 64–67; and 5-azacytidine treatment increases γ-globin synthesis in 
sickle cell anemia and β-thalassemia patients 68,69. Although an MBD protein has not 
been demonstrated to bind directly to the globin gene promoters, MBD2 and its’ 
associated Nucleosome Remodeling and Deacetylase complex (NuRD) have been 
shown to play an indirect role in silencing human embryonic ε- globin and fetal γ-globin 
gene expression 70–73. The NuRD co-repressor complex is composed of the histone 
deacetylase core complex of HDAC1/2, MTA1/2, RBBP4/7 (HDCC), GATAD2A/B and a 
chromatin remodeling enzyme, CHD3/4 74–76. Disrupting interactions of MBD2 with 
NuRD through the HDCC or GATAD2A/CHD4 is sufficient to release MBD2-directed 
transcription repression, thereby making these protein-protein interfaces of therapeutic 
interest 72,77.  
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Figure 1.1 Nucleosome Structure.  
The core histone proteins (H2A, H2B, H3, H4) form tetramers of heterodimers of 
H2A/H2B and H3/H4. These tetramers assemble into an octomer which is wrapped 1.7 
times with ~147 base pairs of DNA to form the nucleosome core particle (NCP). NCPs 
form arrays connected by linker DNA which is bound by histone protein H1 to form 
higher order chromatin structures. Image reprinted with permission 9,10. 
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Figure 1.2 Active and Repressive Histone Modifications 
N- and C-terminal histone tails extend from the globular domains of the histones H2A, 
H2B, H3, and H4. The tails are accessible to enzymes for post-translational covalent 
modification (PTM), including acetylation, methylation, phosphorylation, and 
ubiquitylation. Specific PTMs of certain amino acids within the tails are associated with 
actively transcribed or repressed regions of DNA, depicted on the top and bottom 
halves of the diagram, respectively. Histone tail acetylations are commonly found in 
active gene promoters, while sumoylation tends to repress transcriptional activity.  
Image reprinted with permission 78. 
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Figure 1.3 Methylation-Dependent Transcription Repression 
A) DNA sequences rich in CG motifs (CpG Islands) are often found in promoter and 
enhancer regions upstream of coding sequences. At actively transcribed genes, 
nucleosomes (blue spheres) are spread out on the DNA (black line), making 
euchromatin accessible to transcription factors. B) When CpG islands are methylated 
(red circles), methyl-CpG binding proteins (MBD) bind to the DNA. C) MBD proteins 
recruit their associated remodeling enzymes to compact the nucleosomes into 
heterochromatin and repress transcription initiation.   
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Figure 1.4 The Human Hemoglobin Switch 
The globin locus on chromosome 11 is diagrammed in the bottom panel and the timing 
of the developmental hemoglobin switch is illustrated in the top panel, using the genes 
corresponding color (embryonic ε-globin in blue, fetal γ-globins in green, and adult α- 
and β-globins in red). The globin locus upstream enhancer, the locus control region 
(LCR), and its corresponding DNAse I hypersensitivity sites (HSs) and a downstream 
HS, known as the 3′HS1, are depicted in purple.  
Image reprinted with permission 79. 
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Table 1.1 MBD Family Proteins Binding Preferences, Complexes, and Functions 
 
MBD 
protein* 
Sequence 
preference 
Associated 
Complex 
Function 
    
MeCP2 [A/T]4 + mCG or 
mCAC 
Sin3A, NCoR Histone modification and gene 
silencing 
 
MBD1 TmCGCA or 
TGmCGCA 
SETDB1 and CAF-1 Chromatin Modifying 
    
MBD2 mCGG NuRD Nucleosome remodeling and histone 
deacetylation 
 
MBD3 Non-specific NuRD Nucleosome remodeling and histone 
deacetylation 
 
MBD4 mCG·TG mismatch Thymine glycosylase 
domain 
Mismatch repair of spontaneously 
deaminated methyl-cytosines 
 
* MBD5 and MBD6 do not bind methylated DNA or have a known regulatory complex association 
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Table 1.2 Epigenetic enzyme drug target classes and drug discovery efforts 
 
Epigenetic enzyme classes Approved drugs Clinical trials 
 
DNA Methylation 
DNA methyltransferases 
 
 
X 
 
 
X 
 
Histone Modification 
  
Deacetylases class I, II, IV X X 
Deacetylases class III   
Acetyltransferases  X 
Mono-ADP ribosyltransferases   
Poly-ADP ribosyltransferases  X 
Biotin ligase   
Deiminases   
Glycosyltransferases/glycosidases   
Methyltransferases  X 
Demethylase  X 
Kinases/phosphatases   
E1, E2, and E3 enzymes   
 
microRNA expression 
  
miRNA-regulating proteins   
 
Chromatin Remodeling  
  
ATPase/Helicase   
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CHAPTER 2: STRUCTURAL BASIS OF MECP2 DISTRIBUTION ON NON‐CPG  
METHYLATED AND HYDROXYMETHYLATED DNA 1 
 
Introduction 
As discussed in Chapter 1, methyl‐CpG binding protein 2 (MeCP2) functions as a 
methylation‐dependent transcriptional regulator, tuning the expression of methylated 
target genes throughout neuron maturation. Although MeCP2 was initially identified by 
its affinity for 5‐methylcytosines in CpG (mCG) dinucleotides, advancements in 
methylation sequencing methods have enabled the examination of the developing 
neuronal methylome with greater resolution of non‐CG methylated sites (mCH, where H 
= A, C, or T) and locations of hydroxymethylation. The results of these studies suggest 
the MeCP2 activity most relevant to development may, in fact, be at non‐CG methylated 
sites. Healthy human and murine neurons accumulate mCH and hydroxymethylcytosine 
(hmC) marks while maintaining relatively stable levels of mCG from fetal to adult 
development 1.  MeCP2 binding correlates with mCH density and has higher occupancy 
of genes with elevated mCH levels. These loci appear to have functional roles in 
regulating neuronal gene expression as mouse models of MeCP2 disorders 
demonstrate elevated mCH levels in misregulated genes 2. The most biologically 
significant MeCP2 mCH binding events appear to be to mCA and hmCA. By EMSA, 
                                            
1 This chapter adapted from a manuscript accepted in the Journal of Molecular Biology. 
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MeCP2 demonstrates a lower affinity for mCC, mCT, hmCG and unmethylated DNA, 
than sequences containing mCG, mCA and hmCA sites 3,4. Additionally, ChIP‐seq 
analysis of the murine frontal cortex revealed high mCA and hmCA levels at loci of 
MeCP2 enrichment, suggesting they serve as MeCP2 binding sites in vivo 5.  
The report of MeCP2 mCH binding events holds important implications for the 
structure‐function relationship of methylation‐dependent DNA binding. Seven proteins 
comprise the human methyl‐CpG binding domain (MBD) family, the first discovered, 
MeCP2, and MBD1‐6 6. The protein family members share a homologous MBD domain 
of about seventy amino acids with varying degrees of specificity for symmetrically 
methylated mCG dinucleotides 7. The available crystal and solution structures of MBD 
proteins bound to DNA reveal mCG motifs are similarly recognized across the family 
(PDBs: 1IG4, 3C2I, 2KY8, 3VXX) 8–11. Two conserved arginine residues form bidentate 
hydrogen bonds with the symmetrical guanine bases and pack their guanidinium groups 
against the methyl‐cytosine on the respective strand. A highly‐conserved tyrosine at the 
protein‐DNA interface interacts with the methyl‐cytosine methyl group on one strand 
and is critical to forming a highly‐specific interaction with mCG DNA (Figure 2.1A) 9. The 
genetic, biochemical and biophysical properties of mCG and hmCG binding by MBD 
proteins have been extensively studied 7,12–16. MeCP2, however, is the first MBD protein 
with demonstrated selectivity for asymmetrically methylated mCH and hmCH 2–5. The 
reported evidence even suggests binding methylated and hydroxymethylated CpA 
(h/mCA) dinucleotides mediates the primary effects of MeCP2 on gene expression in 
the developing mammalian brain. Therefore, we sought to understand the features that 
 
 
 
 
 
 43
enable binding these ‘alternative’ motifs, if they are unique to MeCP2 and how they may 
affect the distribution of MBD proteins across the genome. 
In a few sequence‐specific contexts, MBD‐containing proteins have an enhanced 
selectivity for mCG sites. MBD2 has been shown to have an increased affinity for 
mCGG 10, while SELEX experiments with MeCP2 mCG suggested a preference for an 
adjacent [A/T] run of at least four bases 17. In the crystal structure (PDB: 3C2I) 9, the 
MeCP2:mCG complex assembles such that the visible c‐terminal residues of the MBD 
make contacts with the phosphate backbone of the AATT motif in the BDNF promoter 
sequence. We hypothesized this flanking A/T region serves to orient the MeCP2 MBD 
on the mCH site in one direction, positioning Arg111 and Arg133 to interact with a guanine 
on a particular strand. Previous work has suggested the conserved MBD arginines 
contribute unequally to DNA binding 18–20. Therefore, we anticipated the binding of 
asymmetrically methylated mCA and hmC sites would be a strand‐specific recognition 
event and asked if that could be differentially affected by Rett Syndrome‐associated 
mutations. 
Here, we investigated the interactions of MeCP2, and the related protein MBD2, 
with a defined single mCG or mCA site in a native high‐affinity target sequence (Figure 
2.1B and C). We employed nuclear magnetic resonance spectroscopy and isothermal 
calorimetry to obtain robust, quantifiable binding measurements and elucidate the 
molecular details of the accommodation of mCH. As predicted, both MeCP2 and MBD2 
better recognize an adenine substitution of the 3’‐strand guanine (mCA‐3) than on the 
5’‐strand (mCA‐5). MeCP2, however, uniquely maintains a high affinity for mCA‐3 
possibly reflecting the dynamic flexibility of the bound state. The strand specificity is 
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strongly affected by local sequence context and not primarily determined by the 
direction of the AATT motif, as MeCP2 demonstrated very similar affinities for mCAC on 
either stand. Additionally, we examined the effects of Rett syndrome‐associated 
mutations in the MeCP2 MBD on the ability to recognize methylation of CG and CA. 
While the mutations consistently destabilized the folded domain, we found at least three 
of the more common mutations (T158M, P101S, and A140V) retain recognition of both 
mCG and mCA sites. Finally, we compared MeCP2 binding to hemi‐hmCG and hmCA, 
and demonstrate the effects of hmC on the distribution among local binding sites, giving 
insight into a potential mechanism of regulating MeCP2 directed transcriptional control.   
Materials and Methods 
Cloning, Expression, and Purification of the MeCP2 Methyl Binding Domain  
Amino acid residues 77–167 from human MeCP2 was cloned into the pet28a 
(Novagen) vector, untagged. Sequence confirmed constructs were transformed into 
Escherichia coli BL21 Rosetta (DE3) cells (Novagen). Bacterial cultures were grown in 1 
L of lysogeny broth (LB) or isotopically labeled M9 media, in the presence of kanamycin, 
at 37 °C with shaking, until the culture reached an A600 of 0.6 absorbance units. Protein 
expression was induced with 1 mM isopropyl 1-thio-β-D-galactopyranoside for 2-4 h. 
Cells were spun at 4,000 x g for 30 minutes and pellets were stored at -80 °C. Pellets 
were resuspended in 30 mL of lysis buffer [20 mM Tris-HCl (pH 8.0), 6 M Guanidine 
HCl] and homogenized by sonication. Cell extracts were centrifuged at 20,000 × g for 15 
min. The supernatant was dialyzed against 4 L of refolding buffer [20 mM Tris-HCl (pH 
8.0), 150 mM NaCl, 2 mM 2-mercaptoethanol] for 16 hr at room temperature. 
Precipitates were removed by centrifugation at 20,000 × g for 15 minutes. The 
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supernatant was incubated with 35% saturated ammonium sulfate by mixing for 20 
minutes at room temperature and precipitates were removed by centrifugation at 10,000 
× g for 15 minutes. MeCP2 was precipitated from the supernatant with 70% ammonium 
sulfate, slowly added and mixed for 20 minutes, then centrifuged at 20,000 × g for 15 
minutes. MeCP2 protein was resuspended in gel filtration buffer [20 mM Tris-HCl (pH 
8.0), 300 mM NaCl, 1mM dithiothreitol]. The protein solution was syringe filtered and 
loaded onto a pre-equilibrated HiLoad 26/600 Superdex 200 column (GE Healthcare). 
Fractions containing protein as assessed by UV absorbance were combined and flowed 
over a MonoS 10/100 GL column (GEHeathcare), pre-equilibrated with 20 mM Tris-HCl 
(pH 8.0). Bound protein was eluted with a linear gradient of elution buffer [20 mM Tris-
HCl (pH 8.0), 1 M NaCl]. Fractions containing protein as assessed by UV absorbance 
were analyzed via SDS-PAGE and those containing >95% pure MeCP2 protein were 
combined and stored at 4 °C. 
MeCP2 Rhett Syndrome-associated mutations (T158M, R106W, P101S, or 
A140V) were introduced to the MBD construct by site-directed mutagenesis with the 
QuikChange Lightning Kit (Agilent). Mutant proteins were expressed and purified as 
described above. 
MeCP2 Rhett Syndrome-associated mutations (T158M, R106W, P101S, or 
A140V) were introduced to the MBD construct by site-directed mutagenesis with the 
QuikChange Lightning Kit (Agilent). Mutant proteins were expressed and purified as 
described above. 
Cloning, Expression, and Purification of the MBD2 Methyl Binding Domain  
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Amino acid residues 2–72 from chicken MBD2 were previously cloned by this lab 
as a fusion protein with thioredoxin and a hexahistidine N-terminal tag using a modified 
pET32a (Novagen) vector 10. Sequence confirmed constructs were transformed into 
Escherichia coli BL21 Rosetta (DE3) cells (Novagen). Bacterial cultures were grown in 1 
L of lysogeny broth (LB) or isotopically labeled M9 media, in the presence of ampicillin, 
at 37 °C with shaking, until the culture reached an A600 of 0.6 absorbance units. Protein 
expression was induced with 1 mM isopropyl 1-thio-β-D-galactopyranoside for 2-4 h. 
Cells were spun at 4,000 x g for 30 minutes and pellets were stored at -80 °C. Individual 
pellets were resuspended in 30mL of Bacterial Protein Extraction Reagent (B-PER) 
(ThermoFisherScientific) along with protease inhibitor tablets (Roche). Cells were 
homogenized by sonication and the resulting extract was centrifuged at 20,000 × g for 
15 min. The soluble fraction was filtered and flown over a 5 mL HisTrap column (GE 
Healthcare), pre-equilibrated with Buffer A [20 mM Tris HCl (pH 8.0), 300 mM NaCl, 30 
mM imidazole]. The column and bound protein were washed with 5 column volumes 
(CV) of Buffer A, then eluted with Buffer B [20 mM Tris HCl (pH 8.0), 300 mM NaCl, 300 
mM imidazole]. Fractions containing protein as assessed by UV absorbance were 
combined and buffer exchanged into 20 mM Tris HCl (pH 8.0). The protein solution was 
flowed over a Resource-S column (GE Life Sciences) and eluted with a linear gradient 
of elution buffer [20 mM Tris-HCl (pH 8.0), 1 M NaCl]. Fractions containing protein as 
assessed by UV absorbance were combined and applied to a HiLoad 26/600 Superdex 
75 column (GE Healthcare). Fractions containing protein as assessed by UV 
absorbance were analyzed via SDS-PAGE and those containing >95% pure MBD2 
protein were combined and stored at 4 °C. 
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DNA Preparation 
The DNA sequence used for binding studies was derived from the BDNF 
promoter, known to be a native target sequence for MeCP2. Nineteen base 
complementary oligonucleotides with a central methylated cytosine (Integrated DNA 
Technologies) or hydroxymethylated cytosine (Midland Inc) were purchased and 
resuspended in 20 mM Tris HCl (pH 8.0). Complementary strands were annealed by 
heating to 98 °C for one minute and then cooling the solution to room temperature. 
Double stranded DNA was isolated by purification over a MonoQ 10/100 GL ion 
exchange column (GE Healthcare).  
NMR Sample Preparation 
Isotopically labeled MeCP2 or MBD2 purified protein was combined with 10% 
excess double stranded oligonucleotide, or the amount calculated based on measured 
binding affinity to reach the desired fraction bound. The complex was buffer exchanged 
into 10 mM NaPO4, pH 6.5, 1 mM DTT, 10% 2H2O and concentrated to 0.2-1 mM. 
Samples were stored at 4 °C until time of analysis.  
NMR Structure Assignment and Binding Experiments 
Spectra from standard experiments for resonance assignments, distance, and 
torsional angle restraints were collected at 25°C with Bruker Avance III NMR 
spectrometers equipped with a cryogenic probe and operated at a 1H frequency of 500, 
700 or 850 MHz. The data were processed with the NMR‐Pipe program 21 and analyzed 
with the CcpNMR Analysis program 22.  For both the free and DNA‐bound MeCP2 
proteins, backbone resonance was assigned based on 3D HNCO, HNCA, 
CBCA(CO)NH, and HNCACB spectra using standard techniques. Side‐chain 1H and 13C 
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resonances were assigned based on 3D HBHA(CO)NH, HCCH‐TOCSY, H(CCO)NH 
and C(CO)NH spectra 23. The resonance assignment data were deposited to Biological 
Magnetic Resonance Bank with the accession number 26978 for the DNA‐bound 
protein.  
For chemical shift perturbation (CSP) measurements, assigned peaks in the 
mCG‐bound protein HSQC spectrum were transferred to mCH‐bound HSQCs and 
confirmed by 15NOESY. CSPs and peak heights were calculated with the CcpNMR 
Analysis program and plotted with pro Fit 7.0.9 (Quansoft).  
Relaxation dispersion  
Relaxation dispersion spectra (REFS) were collected at 25°C on instruments 
operating at 1H frequencies of 500, 700, and 850 MHz using a constant time CPMG 
delay of 60 ms 24,25. A total of 13 pulse frequencies (νCPMG) ranging from 67 to 1800 Hz, 
with a repeat of two frequencies for error analysis, were collected in an interleaved 
fashion with heating compensation. Data was analyzed using the relax‐nmr software 
26,27 and fit with either the CR72 28 or TSMFK01 29 2‐site models. Model selection was 
based on the AIC technique 30 as implemented in relax‐nmr 31.       
Isothermal Calorimetry Binding Affinity  
Binding affinities were determined by isothermal calorimetry analysis on a 
MicroCal Auto‐iTC200 (Malvern). Proteins and DNA were purified as described above 
and individually buffer exchanged into ITC buffer [10mM potassium phosphate (pH 6.0), 
100mM KCl, and 1mM EDTA]. Protein, DNA, and additional ITC buffer were each 
filtered and degassed under vacuum immediately prior to analysis. In a 37 ºC sample 
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cell, 400 µL of DNA (10‐30 µM) was titrated with 20 injections of 2 µL of protein 
(100‐300 µM) with intervals of 120 s between successive injections. Binding isotherms 
were generated by plotting the corrected heats of binding against the molar ratio of the 
protein to DNA. Data plots were fit to a one‐site binding model and used to calculate 
dissociation constants (Kd), enthalpies of binding (ΔH), stoichiometry (n), and entropy of 
binding (ΔS) with the manufacturer’s software Origin 7.0. 
Dynamic Light Scattering Protein Aggregation Studies 
 MeCP2 A140V mutant MBD protein was purified and concentrated in buffer 
[10mM potassium phosphate (pH 6.0), 1 mM EDTA] with increasing concentrations of 
KCl (100, 300, and 600 mM). The hydrodynamic radii of A140V protein in each 
condition was measured by a DynoPro DLS system (Wyatt Technology Corporation). All 
samples and buffers were filtered through 0.2 μM filters (Millipore) and centrifuged at 
14,000 × g for 2 min before measurement. Three replicates were performed for each 
sample. The hydrodynamic radii and molecular weights of samples were estimated 
using the assumption of globular protein shape. 
Circular Dichroism Secondary Structure Analysis 
Purified MeCP2 MBD and MBD2 MBD protein was buffer exchanged into 100 
mM sodium phosphate pH 7.5 and concentrated to 0.1 mg/ml. CD spectra were 
collected from 190 to 260 nm (0.2 nm interval, 24 nm/min, 0.1 cm path length, 25 °C) on 
a Chirascan Plus CD spectrometer (Applied Photophysics). CD spectra were 
normalized to provide mean residue molar ellipticity in degrees cm−2 dmol−1 residue−1. 
Helical content for each peptide was calculated from the ratio of the observed molar 
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ellipticity at 222 nm to the expected for 100% helix as given by 40,000	ൈ൫ሺ݊ െ 4ሻ ൊ ݊൯, 
where ݊ is the number of amino acid residues 32,33. 
Protein Structure Modeling 
 Text coordinate files were obtained from the RSCB Protein Data Bank 
(www.rcsb.org) 34 and modified to alter DNA bases in the MeCP2 binding pocket. 
Images were produced with PyMOL 35.   
Results 
Thermodynamic analysis of MeCP2 and MBD2 MBD‐mCH interactions 
We asked if the binding of asymmetrically methylated mCA and hmC sites by 
MeCP2 would be a strand‐specific recognition event and if it is unique to MeCP2 among 
the MBD family of proteins. We compared the binding affinities of oligonucleotides 
based on a native MeCP2 binding site in the BDNF promoter with either a symmetrically 
methylated mCG, or an asymmetrically methylated mCA, substituting an adenine for the 
guanine on either the 5’ or 3’ strand. Models are shown of the expected interactions for 
each interface based on the x‐ray crystal structure of the MeCP2:mCG complex (PDB: 
3C2I) (Figure 2.1A‐C) 9.  Binding thermodynamics and dissociation constants were 
measured by isothermal calorimetry (ITC). MeCP2 binds the BDNF promoter 
sequences with a stoichiometry of 1:1, regardless of the methylated cytosine position. 
MeCP2 binding affinity has an apparent Kd value of 50 nM for mCG and 81 nM for 
mCA‐3, and has a significantly lower affinity for mCA‐5 with a Kd value of 409 nM 
(Figure 2.2A‐C and Table 2.1). The differences in binding affinity of MeCP2 for the 
mCA‐5 and mCA‐3 oligomers reflect an unfavorable change in entropy upon binding 
(−TΔS = 2.8 and 7.7 kcal/mol for mCA‐5 and m‐CA3, respectively) that is or is not fully 
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compensated by a more favorable change in enthalpy (ΔH = −11.9 and ‐17.8 kcal/mol 
for mCA‐5 and m‐CA3, respectively). 
However, when the base following the mCA is replaced with a cytosine, high 
affinity binding is maintained for mCAC-3 with a Kd value of 36 nM and the affinity 
increases for mCAC-5 a Kd value of 79 nM (Figure 2.3 and Table 2.1). As with mCA-3, a 
large unfavorable change in entropy for mCAC-3 and mCAC-5 (−TΔS = 5.7 and 8.0 
kcal/mol, respectively), is compensated by a larger favorable change in enthalpy (ΔH = 
−16.3 and -18.1 kcal/mol, respectively).  These results show that MeCP2 maintains high 
affinity binding to mCA-3, mCAC-3, and mCAC-5 through the development of additional 
enthalpically favorable interactions at the expense of a greater reduction in entropy. In 
contrast, MeCP2 does not effectively adapt to mCA-5 with a less favorable change in 
enthalpy as compared to mCpG (ΔH = −11.9 kcal/mol) with a similar change in entropy 
(−TΔS = 2.8 kcal/mol).   
 For comparison, we assessed mCA recognition by MBD2 (Figure 2.4), which 
shows very high selectivity for mCG 13,36 and represents the most evolutionarily ancient 
MBD protein 37,38. We found MBD2 has a slightly lower affinity than MeCP2 for the mCG 
BDNF sequence, with an apparent a Kd value of 157 nM (Figure 2.2D). Unlike MeCP2, 
however, the binding affinity decreased substantially with the substitution of adenine on 
the 3’‐strand. The ITC measurements presented an apparent Kd value of at least 1.5 µM 
(Figure 2.2E), however, the isotherm of binding did not reach a plateau, and therefore 
was unable to be adequately fit with a one‐site model. The failure to accomplish binding 
site saturation, regardless of increased DNA concentration, indicates a low‐affinity and 
non‐specific interaction. 
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Chemical shift perturbations map the transition from the non‐specific to 
methylation‐specific binding mode 
The NMR chemical shift parameter is highly sensitive to changes in the local 
environment and, thereby, subtle changes in the three‐dimensional structure of proteins. 
The residue‐specific changes in the amide backbone of MeCP2 bound to the BDNF 
promoter sequences were monitored by 1H/15N‐Heteronuclear Single‐Quantum 
Correlation (HSQC) NMR spectroscopy and compared using standard chemical shift 
perturbations (CSPs).  In NMR studies of the MBD family proteins, we identified linear 
chemical shift changes that correlate with methylated DNA binding and present in every 
ortholog and paralog examined to date 10,38–40. In particular, two of these resonances 
(Gly27 and Ala30  of MBD2) show large CSPs between the non‐specific and 
methylation‐specific binding modes, such that we have used these resonances as 
reporters of mCG binding 39. We assigned the MeCP2 chemical shifts (BMRB: 26978) 
and likewise found the signature linear CSP of Gly114 and Ala117 upon binding 
methylated DNA (Figure 2.5). To confirm that the chemical shift changes reflect the 
bound state, we collected HSQCs for MeCP2:CpG at 200:220, 400:400, and 400:800 
μM which show that MeCP2 is fully bound under the conditions of our analysis (Figure 
2.6). Therefore, these shifts provide a unique opportunity to directly observe the 
domain’s non‐specific and methylation‐specific binding modes. 
We compared the positions MeCP2 Gly114 and Ala117 or MBD2 Gly27 and Ala30 
peaks when fully bound to mCA-5 and mCA-3. The chemical shifts for both residues 
were almost equivalent in the MeCP2:mCG and MeCP2:mCA‐3 spectra, but in the 
MeCP2:mCA‐5 complex Gly114 shifted from 102.8 ppm downfield in 15N to 103.5 ppm 
and Ala117 shifted downfield in 1H from 6.8 ppm to 6.9 ppm. Based on the measured 
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binding affinity of MeCP2 for mCA-3 and mC-5, MeCp2 is saturated (99.6% and 98.3% 
bound, respectively) under the conditions of the experiment, such that the CSPs reflect 
the bound state. Similar to the CSPs observed in MeCP2, binding to mCA‐5 shifted 
MBD2 resonances for Gly27 downfield from 102.5 ppm in 15N to 106.2 ppm and Ala30 
from 6.85 to 7.15 ppm in 1H. Surprisingly, Gly27 and Ala30 also had large CSPs with an 
adenine substituted on the 3’‐strand, shifting Gly27 downfield in 15N to 104.5 ppm and 
Ala30 to 7.00 ppm in 1H (Figure 2.5). Compared to mCG bound chemical shifts of 
MeCP2, mCA‐5 and mCA‐3 binding generated CSPs throughout the MBD, plotted in 
Figure 2.7A. The largest perturbations clustered in three regions of the protein 
sequence, seen mapped to the crystal structure in Figure 2.7B (PDB: 3C2I) 9. 
Domain structures accommodating of mCA are dynamic in the mCG bound 
conformation  
Relaxation dispersion experiments enable the quantitation of protein motions, 
detecting conformational exchange of dynamic residues. Motions in the MeCP2:mCG 
complex were measured with Carr‐Purcell‐Meiboom‐Gill (CPMG) relaxation dispersion 
pulse sequences. Data was analyzed by relax‐nmr software (see representative 
relaxation curves in Figure 2.8A) and fit with either the CR72 or TSMFK01 2‐site model 
26,27,41. Residues exchanged on different timescales and could not be uniformly fit to a 
single model. Therefore, the residues with faster exchange rates were fit to the CR72 
model 28 and those with very slow exchange rates, within the range of millisecond to 
second time scale, were fit to the TSMFK01 model 29. The extracted fit parameters for 
MeCP2 are listed in Table 2.3 and 2.4, for the CR72 and TSMFK01 models, 
respectively. A large fraction of the well‐resolved peaks displayed dispersion and 
residues with observable exchange are mapped to the MeCP2:mCG complex crystal 
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structure in Figure 2.8B (PDB: 3C2I) 9. Regions displaying dynamic motion were the 
flexible loops at the n‐terminus (R85, G92, M94, E102, T105) and the c‐terminus (N153, 
D157, T160, G161, R162); the major‐groove binding loop and DNA interface (R111, 
K112, G114, R115, R133, S134, V136, E137); and residues in the hydrophobic core 
(V122, L124, I125, K130, A131, F132). Residues with slower exchange are highlighted 
as yellow spheres in Figure 2.8B and clustered in the C‐terminal loop, α‐helix, and 
β‐loop. 
The extracted fit parameters for MBD2 are listed in Table 2.5 and 2.6, for the 
CR72 and TSMFK01 models, respectively. A smaller fraction of the well‐resolved peaks 
displayed dispersion and residues with observable exchange are mapped to the 
MBD2:mCG complex solution structure in Figure 2.8C (PDB: 2KY8) 10. The majority of 
residues displaying dynamic motion were found to be surface exposed (E20, E21) or in 
flexible loops (D3, K4, L28, A58, D60, L61); and in the hydrophobic core (S33, D121, 
V122, Y37, F45, S47, K48, Q50, Y54. Only two were found at the DNA binding interface 
(K44 and R46).  Residues with slower exchange are highlighted as yellow spheres in 
Figure 2.4C and clustered in the C‐terminal loop, α‐helix, and β‐loop.  
Rett Syndrome mutations do not affect MBD preference for mCG and mCA 
Several of the Rett Syndrome‐associated mutations (T158M, R016W, and 
P101S) were examined for recognition of mCG and mCA‐3 by HSQC. All three mutants 
had less defined and dispersed spectra than wild‐type, to varying degrees. The 
spectrum for the R106W mutant lacked peaks for reporter residues Gly114 and Ala117, 
which indicates significant line‐broadening and a lack of stable interaction with mCG or 
mCA.  The spectra for T158M and P101S, however, did show similar chemical shifts for 
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reporter residues, indicating these mutants retain the ability to selectively and 
preferentially bind mCG and mCA (Figure 2.9A-C). 
Rett Syndrome mutation A140V forms MBD protein aggregates 
The A140V mutant MBD was examined for DNA binding activity and recognition 
of mC motifs by HSQC. In the absence of DNA, A140V MBD protein had a significantly 
less ordered spectrum than wild-type off of DNA, however, in the presence of 10% 
excess BDNF mCG DNA, the peaks became as defined and well dispersed as wild-type 
under the same conditions, seen in Figure 2.10. The spectra also displayed similar 
chemical shifts for reporter residues Gly114 and Ala117 to wild-type, indicating this mutant 
retains the ability to selectively and preferentially bind mCG and mCA (Figure 2.11). 
Despite demonstrating specific binding in the presence of DNA under no salt conditions, 
ITC experiments in the presence of 100 mM KCl yielded very noisy data with extremely 
low heat (Figure 2.12). We suspected the protein may be aggregating in the absence of 
DNA, therefore we ran several salt titration experiments. First, we added 100 mM  KCl 
to the A140V:mCG NMR sample and visually observed the immediate precipitation of 
protein. Next, we ran dynamic light scattering experiments on MeCP2 A140V MBD 
protein diluted in buffer with 100 uM and added 100, 300 or 600 μM KCl. The radius 
measurements indicated a positive trend towards increasing particle size and 
polydispersity with increasing salt concentration (Figure 2.12 and Table 2.7). 
Hydroxymethylation reduces MeCP2 affinity for CG but not CA and shifts the 
distribution of MBD populated sites  
To compare the effects of hydroxymethylation on CG and CA DNA binding, we 
synthesized additional oligonucleotides, one hemi‐hydroxymethylated at the CG position 
and one with a hydroxymethylated CA pair, both on the 3’ strand (Figure 2.13A). We 
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examined binding thermodynamics and dissociation constants of MeCP2 by ITC and 
measured an apparent Kd value of 667 nM for hemi‐hmCG and 167 nM for hmCA‐3 
(Figure 2.13B and Table 2.2). When inspected by HSQC, methylation‐specific reader 
residues’ resonances shifted in the MeCP2:hemi‐hmCG complex to 103.1 ppm in 15N 
for Gly114  and 6.8 ppm in 1H for Ala117. By the same method, in the MeCP2:hmCA‐3 
complex the resonances of Gly114 and Ala117 are observed at 102.8 ppm in 15N and 6.8 
ppm in 1H, respectively (Figure 2.13C). The CSPs throughout the domain clustered in 
three regions of the protein sequence (Figure 2.14A), seen mapped to the crystal 
structure in Figure 2.14B (PDB: 3C2I) 9. 
By NMR spectroscopy one can directly measure the relative population of distinct 
states and use differences in chemical shifts to detect the distribution between binding 
sites. To test whether the differences in relative binding affinities of MeCP2 for mCH 
and hmCH correlate with preferential localization, we examined MeCP2 incubated with 
a 1:1 mixture of mCG:mCA (Figure 2.15A) and hemi‐hmCG:hmCA (Figure 2.15B). 
Resonances for both populations of complexes were consistent with a slow exchange 
between mCG and mCA DNA molecules. Hence, the peak height of six residues 
demonstrating non‐overlapping chemical shifts was measured to derive the relative 
populations of the mCA and mCG bound states. In the presence of equal molar 
quantities, the fraction bound to mCG was 68.6 ± 4.1 % and to mCA was 31.4 ± 4 % 
consistent with preferential binding to mCG. When incubated with the 
hydroxymethylated DNAs, 33.4 ± 3.1 % bound to hemi‐hmCG and 66.6 ± 3.1 % bound 
to hmCA‐3, demonstrating MeCP2 now preferentially localizes to the hmCA site (Figure 
2.16A). 
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Discussion 
MeCP2 uniquely recognizes mCA sites in an orientation‐dependent and 
methylation‐specific binding mode 
Our results suggest that the MeCP2 methyl‐binding domain orients to interact 
specifically with the 5’‐strand guanine through Arg111, anchored by Asp121, and with the 
3’‐strand guanine via Arg133. Tyr123, in a hydration shell around the methyl group, 
recognizes the 5’‐strand mC. Substituting adenine for the 5’‐strand guanine disrupts 
hydrogen bonding with Arg111, leaving intact the 3’‐G: Arg133 and 5’‐mC: Tyr123 
interactions. In contrast, the change of the 3’‐strand guanine to adenine results in the 
loss of hydrogen bonds between 3’‐G: Arg133 while maintaining 5’‐G: Arg111 interaction 
and substituting the 5’‐mC with thymine to preserve the methyl‐recognition of Tyr123. 
We originally hypothesized that the orienting of the MeCP2 MBD on DNA is 
driven by the proximal [A/T] region identified in SELEX experiments 17. However, a 
recent preprint presents evidence that the primary MeCP2 bound mCA sequences in 
vivo occur in the mCAC context 42, therefore we asked if the neighboring base could 
alter the strand-specific preference. We found that MeCP2 binds mCAC on either strand 
with high affinity irrespective of the relative position of the BDNF promoter sequence’s 
AATT motif, however, a slight preference was observed for the 3’-mC orientation. This 
suggests that MeCP2 binding to mCA is strand-specific and orientation-dependent, 
driven by a combination of the proximity to an A/T rich region and a preference for sites 
followed by a C or T to G. 
As expected of a major‐groove DNA interaction, the ITC experiments 
demonstrate mCG, mCA‐5, and mCA‐3 binding is an exothermic and enthalpically 
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driven process 43,44. The ITC measurements also reveal the methylated cytosine 
environment does not affect MeCP2:DNA binding stoichiometry but does affect binding 
affinity. We anticipated an mCA‐3 preference for MeCP2 binding and found a less than 
two‐fold change in binding affinity with an adenine substitution of the 3’‐strand guanine, 
compared to a ten‐fold decrease with a substitution on the 5’‐strand (Table 2.1). This 
observation is consistent with computational quantum mechanical modelling that 
suggested Arg133 is more ﬂexible than Arg111, which is strongly ﬁxed by hydrogen 
bonding with the Asp121 side chain, and that the Arg133 guanidinium group rotates 
towards Arg111 in the presence of a 5’‐strand methylated base to create a 
‘closed/locked’ state (Figure 2.1) 18. Our relaxation dispersion measurements of the 
MeCP2 MBD bound to mCG DNA provide additional support for this model, measuring 
an exchange rate approximately 860x faster for Arg133 than Arg111 (Table 2.3 and 2.4).  
Remarkably, binding to mCA-3, mCAC-5 or mCAC-3 is more exothermic than 
mCG to compensate for a substantial decrease in entropy of 2-5 kcal/mol (Table 2.1). 
This suggests that MeCP2 forms additional enthalpically favorable hydrogen bonds 
and/or ionic interactions to adapt to binding alternative substrates with high affinity, 
however, the mCH-bound state is more restricted with fewer degrees of freedom. This 
leads us to speculate that symmetrical mCG binding sites allow more flexibility in 
orientation on the DNA and perhaps switching between the recognized methyl group on 
either strand.  
In the methylation‐specific binding mode, the MBD’s major‐groove binding β‐loop 
is stabilized by the hydrogen bonding between the 5’‐strand guanine and Arg111, at the 
base of β‐strand 1. Therefore, the resonances of loop residues are reporters of 
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methylation‐specific and non‐specific binding by analysis of chemical shifts 39.  The 
linearity of the chemical shifts of Gly114and Ala117 of MeCP2 between the different DNAs 
is characteristic of fast exchange between the major conformations (Figure 2.5). We 
varied the ratio of bound MeCP2 and observed no measurable change in peak position 
(Figure 2.6), therefore confirming that the shift of reporter residues do not reflect 
exchange between bound and free but instead reflect exchange between methylation 
specific and non-specific binding modes (as we have described previously for MBD2 
and MBD3) 39. When bound to mCA‐5, the substitution of the 5’‐strand guanine for 
adenine and Arg111 fails to stabilize the loop, thus MeCP2’s Gly114 and Ala117 chemical 
shifts occur closer to their conformation on unmethylated DNA. When compared across 
the domain, residues with CSPs above 0.05 ppm between mCG and mCA bound 
MeCP2 clustered around the DNA interface and the major‐groove binding loop, as well 
as the more distant helix 1 (Figure 2.7). In these regions and overall, the measured 
CSPs are fewer and smaller in the presence of mCA‐3 than mCA‐5, consistent with the 
mCA‐3 bound state more closely resembling the mCG-bound MeCP2 MBD.  
In contrast, the affinity of the MBD2 MBD for BDNF DNA is severely decreased 
by substitution of adenine, even on the 3’‐strand (Figure 2.2 D and E). The methylation 
selectivity for mCA is also diminished, although less so for mCA‐3, as indicated by the 
chemical shifts of Gly27 and Ala30 away from the specifically mCG‐bound conformation 
(Figure 2.5) and towards the non‐specifically CG‐associated conformation 39. Taken 
together, the HSQC measurements demonstrate methylation‐specific binding is 
orientation dependent for both MeCP2 and MBD2. They also imply mCA‐3 selectivity is 
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unique to MeCP2 among the MBD family proteins, and indicate that changes in helix 1 
could contribute to accommodating mCA.  
DNA binding proteins can have greater promiscuity in target sequences through 
conformational flexibility within the protein interaction surface 45. Studies of transcription 
factor binding of DNA target motifs have shown flexibility can be essential to function 46 
and simulations illustrate that target sequence recognition is a dynamic process 47,48. 
Relaxation dispersion measurements can detect dynamic processes, such as side chain 
reorientation, loop motion, secondary structure changes and hinged domain 
movements. The dispersion observed in the MeCP2:mCG complex indicates residues 
at the DNA interface undergo microsecond to millisecond motions (Table 2.3 and 2.4). 
This exchange likely represents the rapid breaking and reforming of salt bridges and 
hydrogen bonds between coordinating amino acids, as well as direct amino acid‐base 
interactions. The loops of the N‐ and C‐terminal unstructured regions demonstrated the 
fastest exchange rates which likely reflects a dynamic transient interaction between the 
amino‐acid residues and the DNA backbone, leading to large chemical shifts, noted with 
orange in Figure 2.8 49. The majority of residues with distinguishable chemical shifts 
along helix 1 and the β‐loop display slower exchange, noted in yellow in Figure 2.8, on 
the millisecond to second time scale, consistent with larger coordinated motions. Taken 
with the chemical shift analysis, the relaxation dispersion measurements further indicate 
flexibility and dynamics in helix 1. In contrast, helix 1 of MBD2 is shorter and held closer 
to the core β‐sheet by a shorter loop, possibly restricting its structural plasticity and 
ability to form alternative interactions with DNA (Figure 2.4). 
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Therefore, we postulate MeCP2 retains high affinity for non‐CG methylated DNA 
due to flexibility in its MBD when bound to DNA along with an increase in the length of 
helix 1. As we have described previously for MBD4 40, MeCP2 has a small insertion of 4 
amino acids that extends helix 1 by one additional turn as compared to MBD2. This 
addition contributes to a larger hydrophobic core possibly stabilizing the isolated 
domain. Consistent with this hypothesis, the circular dichroism spectra demonstrate that 
when free in solution MeCP2 MBD adopts a better-defined structure than the MBD2 
MBD, which more resembles a random coil (Figure 2.17). Likewise, the HSQC spectrum 
of MeCP2 MBD in the absence of DNA is well-dispersed indicative of a folded domain, 
while that of MBD2 MBD is significantly broadened until bound to DNA, indicating it 
undergoes a disorder-to-order transition upon binding (Figure 2.18). We suggest that 
increased stability of the isolated MeCP2 MBD allows the protein to more readily adapt 
to alternative binding sequences by allowing the residues involved in DNA binding to 
sample a larger conformational space, without an increase in entropy sufficient to 
overcoming the free energy barrier to unfolding 45,48. The relaxation dispersion observed 
in the hydrophobic core of MeCP2 is consistent with the ability of the protein structure to 
breathe, which enables recognition of more than one binding sequence and allows for 
accommodation of mCA motifs. 
The MBD2 MBD is mostly disordered off of DNA and may behave like an 
intrinsically disordered protein in targeting CG motifs by rapidly sampling partially folded 
states for finding the most favored conformation 50. This conformation is often stabilized 
upon binding more from forming intermolecular interactions, than from the energetics of 
folding 51, therefore MBD2 may be less tolerant of adjustments to the binding 
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interactions available in an mCA dinucleotide. We conclude the larger entropic cost of 
ligand‐induced folding limits the range of sequences that provide sufficient interactions 
to stabilize the methylation-specific binding conformation of MBD2. 
Rett Syndrome associated mutations in the MeCP2 MBD to not eliminate 
methylation recognition function  
Interestingly, mutations in the MeCP2 that disrupt the domain architecture do not 
preferentially affect selectivity for mCG or mCA sequences. The R016W mutation 
inserts a bulky tryptophan residue into the domain’s hydrophobic core, destabilizing the 
MBD as evident from the decrease in discretely defined peaks in an HSQC spectrum. 
The presence of neither mCG or mCA‐3 DNA ordered the R106W MBD sufficiently to 
observe peaks for the Gly114 and Ala117 reporter residues (Figure 2.12C). The less 
disruptive mutations of T158M, P101S, and A140V increase the domain motions, as 
evident from the broadening of residue peaks, but they retain the ability to bind mC in 
the methylation‐specific binding mode in the preferred orientation. The chemical shifts 
indicate the loss of hydrogen bonds between Arg133 and the 3’‐strand guanine of the 
mCA‐3 sequence does not inhibit mC recognition even when the MBD is moderately 
destabilized (Figure 2.9 and Figure 2.11). We were unable to sufficiently concentrate 
the A140V mutant protein for ITC analysis due to aggregation (Figure 2.12); however, 
our results support the recent suggestion that mutations in the MBD may not cause Rett 
by affecting selectivity for methyl‐cytosines. Instead, our data are consistent with the 
dysfunction associated with changes in MeCP2 levels in both MeCP2‐null and 
‐overexpressing mice 2,52–54. Furthermore, Rett Syndrome‐associated mutations lead to 
much lower MeCP2 cellular concentrations as compared to wild‐type 55. Perhaps 
aggregates of destabilized MeCP2 more readily signal for degradation and the 
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remaining soluble protein cannot fully occupy high affinity sites, creating a dilution effect 
that is further amplified by the lower overall affinity of the mutant protein for both mCpA 
and mCpG sites. Our findings further support the therapeutic potential of re‐stabilizing 
mutant MeCP2 to restore native protein function, but this model of MeCP2 dysfunction 
needs to be rigorously tested via extensive investigation. 
Hydroxymethylation reduces MeCP2 affinity for CG while maintaining selectivity 
for CA 
By HSQC, there were clear chemical shift differences between the hemi‐hmCG 
and hmCA‐3 bound states, however, the reporter residues of the methylation bound 
state were relatively close to each other and mCG (Figure 2.13C). The ITC derived Kd is 
a highly sensitive measure of global binding affinity, whereas the chemical shift changes 
of Gly114 and Ala117 reflect distribution between CG specific and non‐specific binding 
modes. Our data indicates MeCP2 recognizes hmC in a similar manner as mC, despite 
not retaining a high affinity for hemi‐hmCG. From examining the 3D models based on 
the MeCP2:mCG crystal structure (Figure 2.13A) (PDB: 3C2I) 9, we expected both 
hemi‐hmCG and hmCA‐3 would retain the 5’‐G:Arg111 interaction; supply a 
methyl‐group for recognition by Tyr123; and, by adding a hydroxyl group to the mC that 
packs against Arg133, potentially disrupt the hydrophobic interaction. The preservation of 
the 5’‐G:Arg111 interaction continues to stabilize the β‐loop in which Gly114 and Ala117 
reside. As such, their corresponding methylation specific reporter peaks in the 
hemi‐hmCG and hmCA HSCQs do not shift far from mCG (Figure 2.13C). Furthermore, 
the hemi‐hmCG bound conformation remains highly similar to mCG with the fewest and 
least extreme changes in chemical shift (Figure 2.14).  
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In contrast, hydroxymethylation of the 5’‐mC significantly changes the binding 
affinity of MeCP2. Our ITC measurements demonstrate only a two‐fold difference in the 
apparent Kd between mCA‐3 and hmCA‐3, however, hydroxymethylation of the same 
cytosine position in the hemi‐hmCG oligo resulted in a greater than ten‐fold decrease 
from the mCG binding affinity (Figure 2.13B and Table 2.2). This observation implies 
that the anchoring of Arg133 through hydrogen bonding with the mCG 3’‐strand guanine 
impedes the accommodation of a hydroxyl group on the 5’‐strand mC. When adenine 
replaces the 5’‐strand guanine, Arg133 is ‘unlocked’ and released from the 
hydroxyl‐imposed steric tension. 
 We asked if the changes in binding affinity with hydroxymethylation would reflect 
a change in the distribution of MeCP2 among mC sites. The Kd measurements would 
suggest MeCP2 equitably occupies mCG and mCA‐3 sites. Peak heights in an HSQC 
provide information about the relative populations of states. In the presence of a 1:1 
mixture of mCG:mCA‐3 DNA, peaks with distinct chemical shifts between mCG and 
mCA‐3 bound conformations (Figure 2.15A) indicated nearly 70% of the MeCP2 present 
was mCG bound (Figure 2.16A). Alternatively, upon addition to a 1:1 mixture of 
hemi‐hmCG:hmCA‐3 DNA (Figure 2.15B), the MeCP2 populations shifted to over 65% 
hmCA‐3 bound (Figure 2.16A), consistent with the discrepancy in binding affinity. To 
date, hmCA has rarely been observed in base‐level resolution mapping of the 
hydroxymethylome of the human neurons 5, however, hmCG is known to accumulate in 
the brain throughout development, especially in the gene bodies of highly expressed 
genes 1,14,56.  Therefore, our findings support a model in which hydroxymethylation 
could serve as a molecular switch to effectively redistribute MeCP2 from mCG to 
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h/mCA‐3 sites, modeled in Figure 2.16B, and warrant further investigation into the role 
of MeCP2 function at mCA‐3 and hmCA‐3 loci. 
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Figure 2.1 MeCP2 MBD binding site with mCH  
Models comparing the (a) mCG complex, and highlighting in yellow the hydrogen bonds 
disrupted by substituting an AT base pair for one CG on the (b) 5’ or (c) 3’ strand. The 
sequence of the oligonucleotide used in the study is below each model, methylated 
bases are in red and substitutions are bolded.  
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Figure 2.2 MeCP2 and MBD2 binding affinity for mCH  
ITC titrations of the MeCP2 MBD with (a) mCG, (b) mCA‐5 and (c) mCA‐3 
oligonucleotides, and of the MBD2 MBD with (d) mCG and (e) mCA‐3. The lines 
represent the fit of the data (Table 2.1). 
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Figure 2.3 MeCP2 binding affinity for mCAC  
ITC titrations of the MeCP2 MBD with (a) mCAC‐5 and (b) mCAC‐3 oligonucleotides. 
The lines represent the fit of the data (Table 2.1). 
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Figure 2.4 Structural alignment of MeCP2 and MBD2  
Overlay of the crystal structure of the MeCP2 MBD:mCG DNA complex (cyan) and 
NMR ensemble average structure of the MBD2 MBD:mCG DNA complex (purple).  
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Figure 2.5 Binding modes of MeCP2 and MBD2 to mCH  
Top: A schematic illustrating the exchange of an MBD between the non‐specific (left) 
and methylation‐specific (right) binding modes. mC bases are represented as red 
circles.  
Bottom: An overlay of 15N HSQC spectra for key reporter residues of wild‐type MeCP2 
and MBD2 bound to CG, mCG, mCA‐5, and mCA‐3.  
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 Figure 2.6 MeCP2 chemical shifts upon binding unmethylated DNA at varying 
concentration ratios  
15N HSQC spectra of the methyl‐binding domain of MeCP2 on unmethylated BDNF 
DNA at ratios of 200:220 (teal), 400:400 (green) and 400:800 (purple) micromolar. 
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Figure 2.7 Structural changes induced by binding of MeCP2 to mCH 
(a) Bar graphs showing the CSPs induced by MeCP2 binding to mCA‐5 (top) and 
mCA‐3 (bottom), compared to mCG bound chemical shifts. Sequence regions with the 
greatest CSPs are indicated. (b) Mapping of the CSPs induced by mCA‐5 (left) and 
mCA‐3 (right) binding to MeCP2 on the crystal structure of mCG‐MeCP2 (PDB 3C2I). 
Residues with CSPs larger than 0.5 (yellow) and 1.0 (orange) p.p.m. are represented as 
sticks.  
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Figure 2.8 Internal dynamics of MeCP2 and MBD2 bound to mCG 
(a) Representative relaxation dispersion curves of residues in the MeCP2:mCG 
complex, demonstrating slow exchange fit with the TSMFK01 model (left) or fast 
exchange fit with the CR72 model (right). Residues of (b) MeCP2 and (c) MBD2 
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displaying slow (yellow) and fast (orange) exchange are shown as spheres in the 
structural maps.  
  
Figure 2.9 mCH recognition by Rett Syndrome‐associated mutation in the MBD of 
MeCP2  
15N HSQC spectra of the MeCP2 MBD with Rhett Syndrome‐associated mutations (a) 
T158M, (b) P101S, (c) R106W, and (d) A140V on mCG (navy) and mCA‐3 (red) DNA. 
Location of reporter residues for methylation‐specific binding are highlighted in yellow. 
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Figure 2.10 DNA binding by Rett Syndrome‐associated mutation A140V in the 
MBD of MeCP2  
15N HSQC spectra comparing free protein (top) and mCG bound (bottom) wild-type 
MeCP2 MBD (red) with Rhett Syndrome‐associated mutation A140V (blue or teal). 
Location of reporter residues for methylation‐specific binding are highlighted in yellow. 
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Figure 2.11 mCH recognition by A140V mutation in the MBD of MeCP2  
15N HSQC spectra comparing MeCP2 A140V (top) binding mCG (teal) with mCA-3 
(magenta) and (bottom) wild-type MeCP2 MBD (orange) with A140V (magenta) on 
mCA-3. Location of reporter residues for methylation‐specific binding are highlighted in 
yellow.  
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 Figure 2.12 Aggregation study of A140V Rett Syndrome‐associated mutation in 
the MBD of MeCP2  
ITC titrations of the MeCP2 MBD with (a) mCAC‐5 and (b) mCAC‐3 oligonucleotides. 
The lines represent the best estimated fit of one-site binding model. Representative 
DLS histograms of the hydrodynamic radii of MeCP2 A140V MBD protein in the 
presence of (c) 100 mM and (d) 300 mM KCl. 
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Figure 2.13 MeCP2 MBD binding to hydroxymethylated CH 
(a) Models of the MeCP2 MBD binding site comparing the hemi‐hydroxymethylated CG 
(left) and hydroxymethylated CA‐3 (right) complexes, highlighting in yellow the predicted 
hydrogen bonds disrupted compared to the mCG bound crystal structure. Sequence of 
the oligonucleotide used in the studies are below each model, including methylated 
cytosines (red) and hydroxymethylated bases (underlined). (b) ITC titrations of MeCP2 
MBD with hemi‐hmCG (left) and hmCA‐3 (right). The lines represent the fit to a one‐site 
model (Table 2.2). (c) An overlay of 15N HSQC spectra for key reporter residues 
Gly114(left) and Ala117(right) of wild‐type MeCP2 bound to mCG (gray), hemi‐hmCG 
(red) and hmCA‐3 (navy).  
 
 
 
 
 
 
 79
  
Figure 2.14 Structural changes induced by binding of MeCP2 to hmCH 
(a) Bar graphs showing the CSPs induced by MeCP2 binding to hmCA‐3 (top) and 
hemi‐hmCG (bottom), compared to mCG bound chemical shifts. Sequence regions with 
the greatest CSPs are indicated. (b) Mapping of the CSPs induced by hemi‐hmCG (left) 
and hmCA‐3 (right) binding to MeCP2 on the crystal structure of mCG‐MeCP2 (PDB 
3C2I). Residues with CSPs larger than 0.5 (yellow) and 1.0 (orange) p.p.m. are 
represented as sticks. 
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Figure 2.15 HSQC difference peaks in MeCP2 MBD on methylated and 
hydroxymethylated CH 
15N HSQC spectra of key reporter residues of MeCP2 bound to (a) mCG (red), mCA‐3 
(blue) and a 1:1 mixture (green) with 1D slices on left and 2D overlays on right. Below, 
in (b) are reporter residues of MeCP2 bound to hemi‐hmCG (red), hmCA‐3 (blue) and a 
1:1 mixture (green) with 1D slices on left and 2D overlays on right.  
 
  
 
 
 
 
 
 81
  
Figure 2.16 MeCP2 MBD distribution on methylated and hydroxymethylated CH 
(a) Box plot of the fraction of MeCP2 bound to mCG:mCA‐3 and hmCG:hmCA‐3 (n=6). 
(b) Model of distribution shift from mCG motifs to mCA‐3 motifs (red circles) upon 
hydroxymethylation (green circles) of both sites.  
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Figure 2.17 Secondary Structure of MeCP2 and MBD2 MBDs off DNA  
Far-UV circular dichroism spectra of the isolated methyl‐binding domain of MeCP2 
(blue) and MBD2 (red) with the characteristic shape and magnitude of an alpha-helical 
protein and random coil structure, respectively. 
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Figure 2.18 MeCP2 and MBD2 structural changes induced by binding DNA  
15N HSQC spectra of the methyl‐binding domain of (a) MeCP2 off DNA (left, purple) or 
on mCG DNA (right, red) and (b) MBD2 off DNA (left, purple) or on mCG DNA (right, 
red). 
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Table 2.1 Binding affinity of methyl‐binding domains to methylated BDNF DNA  
Complex KD(nM)  n  ∆H (kcal/mol)  ‐T∆S (kcal/mol)  ∆G (kcal/mol)  
MeCP2:mCG  50 ± 17 1.1 ‐13.7 ± 0.3 3.3 ‐10.4 ± 0.2 
MeCP2:mCA‐5 409 ± 87 1.3 ‐11.9 ± 0.3 2.8  ‐9.1 ± 0.1 
MeCP2:mCA‐3  81 ± 13 0.9 ‐17.8 ± 0.2 7.7 ‐10.1 ± 0.1 
MBD2:mCG 157 ± 23 1.1 ‐15.9 ± 0.2 6.2 ‐9.7 ± 0.1 
MBD2:mCA‐3 >1900 0.9 ‐11.8 ± 0.9 3.7  ‐8.1 ± 0.2 
MeCP2:mCAC‐5  79 ± 17 0.9 ‐18.1 ± 0.2	 8.0 ‐10.1 ± 0.1 
MeCP2:mCAC‐3 36 ± 10 0.8 ‐16.3 ± 0.3	 5.7 ‐10.6 ± 0.2 
 
 
Table 2.2 Binding affinity of MeCP2 to hydroxymethylated BDNF DNA  
Substrate KD(nM)  n  ∆H (kcal/mol)  ‐T∆S (kcal/mol)  ∆G (kcal/mol)  
hemi‐hmCG 667 ± 129 0.7 ‐10.5 ± 0.4 1.7 ‐8.8 ± 0.1 
hmCA‐3 161 ± 26 1.0 ‐18.1 ± 0.3 8.4 ‐9.6 ± 0.1 
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Table 2.3 15N NMR relaxation data for the backbone N‐H groups of the 
MeCP2:mCG complex fit to the CR72 model 
Residue Rate (sec‐1) Fraction Population A ω (ppm) 
R 85 637.32 ± 137.11 0.87 ± 0.07 0.86 ± 0.33 
E 102 1347.57 ± 66.03 0.99 ± 0.00 2.82 ± 0.11 
T 105 3240.66 ± 807.13 1.00 ± 0.00 9.04 ± 0.94 
G 114 4673.68 ± 970.73 1.00 ± 0.00 13.32 ± 1.13 
D 121 1217.47 ± 356.34 0.97 ± 0.04 2.97 ± 0.71 
V 122 878.57 ± 303.22 0.98 ± 0.04 1.45 ± 0.55 
N 126 382.60 ± 243.82 0.99 ± 0.07 2.28 ± 0.27 
A 131 1794.87 ± 187.65 0.96 ± 0.05 1.63 ± 0.52 
R 133 2968.64 ± 778.36 0.99 ± 0.03 2.67 ± 1.38 
D 147 4227.73 ± 692.19 0.99 ± 0.04 2.03 ± 1.28 
F 155 2380.65 ± 511.80 1.00 ± 0.01 3.59 ± 0.91 
T 160 1091.09 ± 337.70 0.84 ± 0.09 1.25 ± 0.84 
 
 
 
Table 2.4 15N NMR relaxation data for the backbone N‐H groups of the 
MeCP2:mCG complex fit to the TSMFK01 model for very slow exchange 
Residue Rate (sec‐1) ω (ppm) 
A 79 1.04 ± 0.10 3.08 ± 0.26 
R 84 4.77 ± 0.53 2.18 ± 0.20 
M 94 3.05 ± 0.32 3.39 ± 0.38 
G 103 1.96 ± 0.07 8.41 ± 0.28 
R 111 3.46 ± 0.40 6.17 ± 0.72 
K 112 2.79 ± 0.31 5.77 ± 0.71 
R 115 3.15 ± 0.20 5.76 ± 0.31 
G 118 2.24 ± 0.34 5.91 ± 0.90 
I 125 3.02 ± 0.18 5.58 ± 0.34 
G 129 0.82 ± 0.06 11.04 ± 0.68 
K 130 2.62 ± 0.06 5.33 ± 0.13 
F 132 2.91 ± 0.20 5.51 ± 0.37 
V 136 3.54 ± 0.22 9.70 ± 0.58 
E 137 1.91 ± 0.30 8.44 ± 1.52 
L 138 3.97 ± 0.23 5.92 ± 0.33 
A 140 1.76 ± 0.15 6.27 ± 0.45 
V 145 4.79 ± 0.13 5.27 ± 0.13 
G 146 3.27 ± 0.08 2.76 ± 0.07 
S 149 0.88 ± 0.05 9.58 ± 0.44 
L 150 1.24 ± 0.06 2.90 ± 0.12 
D 151 0.87 ± 0.04 6.19 ± 0.26 
N 153 2.78 ± 0.09 3.15 ± 0.90 
G 161 3.69 ± 0.45 2.52 ± 0.27 
R 162 6.43 ± 0.67 9.51 ± 1.04 
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Table 2.5 15N NMR relaxation data for the backbone N‐H groups of the MBD2:mCG 
complex fit to the CR72 model 
Residue Rate (sec‐1) Fraction Population A ω (ppm) 
L 28 1246.26 ± 500.75 1.00 ± 0.04  3.52 ± 0.75  
S 33 2200.35 ± 436.01 0.98 ± 0.03 2.03 ± 0.91  
D 34 1703.77 ± 311.43 0.97 ± 0.04 2.52 ± 0.72  
V 35 1268.42 ± 275.68 0.99 ± 0.03 1.96 ± 0.62  
Y 37 3075.67 ± 559.82 0.99 ± 0.03 2.67 ± 1.18  
F 45 1267.34 ± 495.17 0.98 ± 0.05 3.87 ± 0.79 
R 46 1511.04 ± 746.02  0.99 ± 0.08 4.03 ± 1.26  
S 47 2031.31 ± 652.61  0.99 ± 0.05 3.16 ± 1.17  
Y 54 1531.25 ± 377.27 0.99 ± 0.01 3.31 ± 0.71  
D 60 1277.35 ± 472.82 1.00 ± 0.02 3.67 ± 0.68  
 
 
 
Table 2.6 15N NMR relaxation data for the backbone N‐H groups of the MBD2:mCG 
complex fit to the TSMFK01 model for very slow exchange 
Residue Rate (sec‐1) ω (ppm) 
D 3 1.33 ± 0.04 3.79 ± 0.09 
K 4 1.15 ± 0.02 3.56 ± 0.04 
E 21 7.22 ± 0.21 3.89 ± 0.09 
V 22 11.34 ± 0.56 6.64 ± 0.29 
K 44 3.41 ± 0.16 6.38 ± 0.29 
K 48 2.18 ± 0.23 6.40 ± 0.63 
Q 50 2.90 ± 0.27 10.25 ± 0.93 
A 58 1.77 ± 0.06 3.81 ± 0.12 
L 61 2.88 ± 0.19 6.05 ± 0.39 
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Table 2.7 Dynamic light scattering of MeCP2 A140V mutant MBD  
[KCl] (mM) Radius (nm)  Polydispersity (%) 
100 62.9 ± 2.3 23 ± 2.1 
300 129.4 ± 27.8 Multimodal 
600 536 ± 139  Multimodal 
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CHAPTER 3: INTRODUCTION TO THE NURD COMPLEX ARCHITECTURE AND 
FUNCTION 
 
Nucleosome Remodeling Deacetylase Complex 
The nucleosome remodeling and deacetylase complex is a regulator of 
chromatin structure and gene expression conserved in animals evolutionarily through 
sponges 1. As mentioned in Chapter 1, the megadalton complex is comprised of a 
combination of subunits: MBD2/3, HDAC1/2, MTA1/2, RBBP4/7, GATAD2A/B and 
CHD3/4. NuRD has generally been considered a transcriptional corepressor complex, 
as MBD2 targets the histone deacetylase (HDAC1/2) and nucleosome repositioning 
ATPase (CHD3/4) to induce gene silencing at methylated CpG islands 2. However, the 
presence of MBD3 excludes MBD2 from the complex and displays specificity for CG 
sequences but not enhanced affinity for mC 3–6. In fact, MBD3-NuRD is found at 
transcriptionally active enhancers and promoters, suggesting that NuRD plays a diverse 
set of roles in maintaining and restructuring chromatin organization 7,8.  
Proteomic studies provide insight into the stoichiometric ratios and special 
proximity of NuRD components 9 and structural studies have characterized a few 
interactions between subunit domains and chromatin 10,11. Crystallographic and NMR 
structures illustrate the interfaces of MBD2/3 and methylated DNA 12, the MBD2 coiled-
coil domain and GATAD2A conserved region 1 (CR1) 13, the WD40 domain of RBBP4/7 
with the tail of H4 14 and two C-terminal α-helical regions of MTA1 10,11, the ELM2-SANT 
domains of MTA1 wrapping around HDAC1 15, and an N-terminal peptide of H3 
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methylated at Lys9 bound to PHD2 finger of CHD4 16. Enzymatic assays demonstrate 
direct deacetylase activity of HDAC1/2 and histone proteins containing acetylated lysine 
residues 17, as well as the helicase activity of CHD3/4 in the presence of nucleosomes 
and ATP 18. Biochemical experiments demonstrate additional interactions between 
HDAC1/2 and RBBP4/7 10, the PHD1 finger of CHD4 and unmodified H3 tails 16, the 
MBD2 intrinsically disordered region (IDR) and the histone deacetylase core complex 
(HDCC) of HDAC1/2, MTA1/2, and RBBP4/7 19, and possibly GATAD2A and histones 20 
and/or CHD4 9,13. The confirmed interactions are mapped in Figure 3.1, however, the 
full picture of complex formation is not complete as the function of conserved domains 
in MTA1/2, GATAD2A/b and CHD3/4 have yet to be determined. 
Methyl-CpG Binding Domain Protein 2 MBD2 
 MBD2 and MBD3 are the evolutionarily most ancient members of the methyl-
CpG binding domain (MBD) protein family. Originating as a single gene product with 
selectivity for methylated cytosines (mC) in invertebrates, the sequence likely duplicated 
and subsequently diverged to separate functions in vertebrates 21. Although the 
mammalian MBD2/3 proteins share ~70% sequence identity 22, MBD2 retains mC 
selectivity 23 and changes in critical residues at the DNA interface of MBD3 have 
reduced binding preference for methylated DNA 6,24. Both proteins associate with the 
NuRD complex in a mutually exclusive manner, but only MBD2-NuRD has been 
implicated in transcription repression 4.  
The human MBD2 gene encodes two isoforms with a core 30 kDa protein 
containing an N-terminal MBD domain, a central intrinsically disordered region, and a C-
terminal coiled-coil motif. Knockdown of MBD2 inhibits the growth of human cancer cells 
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lines 25,26 and xenograft tumors 27 and MBD2-definicient mice are resistant to 
tumorigenesis 28,29. MBD2 also contributes to the developmental silencing of embryonic 
and fetal globin genes 30, re-expression of which are promising avenues for treating 
hemoglobinopathies.  Knockout of several NuRD complex proteins is embryonic lethal 
(HDAC1,GATAD2A/B, CHD4) 31–33, however, MBD2 knockout mice are viable and 
fertile, thereby making it a more desirable therapeutic target.  
Metastasis associated 1 family member protein 2 MTA2 
The founding member of the MTA protein family was identified as a differentially 
expressed gene in a metastatic rat mammary adenocarcinoma cell line 34. In human 
cancers, MTA1 and MTA2 are the most commonly upregulated genes and correlate 
with tumor invasiveness, chemotherapeutic resistance, poor clinical prognosis and low 
survival rates 35. The MTA2 amino acid sequence is 68% homologous to MTA1 and 
shares the typical architecture with Bromo-Adjacent Homology (BAH), egl-27 and MTA1 
homology (ELM2), SWI, ADA2, N-CoR, TFIIIB-B (SANT) and GATA-like zinc-finger 
(ZnF) domains. The ELM2 and SANT domains of MTA1 have been crystallized in 
complex with HDAC1 15 and helices in the less structured c-terminal region of MTA1 
have been crystallized in complex with RBBP4/7 10,11. The MTA family zinc-finger is 
atypical with little homology to other GATA domains and the MTA1 ZnF has been 
shown to immunoprecipitate RBBP4/7 and implicated in facilitating FOG-2 mediated 
transcriptional repression 36. The MTA2 ZnF has not been characterized and, in Chapter 
4, we present findings of binding assays with various substrates to further elucidate 
function. 
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GATA zinc finger domain containing protein 2A GATAD2A 
GATAD2A and GATAD2B share 41% protein sequence identity with 2 regions 
highly conserved in animals and between the two proteins, conserved region 1 (CR1) 
with 83% identity and conserved region 2 (CR2) with 74% identity. Little work has been 
done to define GATAD2A's biological function beyond establishing knocking-out the 
gene in mice is embryonic lethal and confirming its presence in the NuRD complex 31,37. 
Our previous studies have extensively characterized the interaction of CR1 with a 
coiled-coil domain in MBD2/3 and demonstrated its necessity for the recruitment of 
GATAD2A and CHD4 to the NuRD complex. Recent work has further indicated that the 
presence of GATAD2A in NuRD is critical to the complex recruitment to sites of DNA 
damage 38. A limited examination of CR2 led to the identification of histone tail binding 
activity 20, however, our previously published work on the MBD2/GATAD2A interaction 
13 led to a hypothesis that this region is also involved in the interaction with CHD4, 
which is investigated in Chapter 4.  
Chromodomain helicase DNA binding protein 4 CHD4 
The CHD family of proteins belong to the SNF2/RAD54 helicase family of genes 
and participate in the epigenetic regulation of transcription 39 and facilitation of DNA 
repair 40–42. The CHD3 and CHD4 functions within the NuRD complex to modify 
nucleosome positioning and control target gene expression. Mutations in CHD3/4 have 
been associated with endometrial tumors 43,44 and developing autoimmunity against 
them causes dermatomyositis 39, while knockdown and knockout of CHD4 in cell lines 
and xenograft models of osteosarcoma and acute myeloid leukemia sensitize tumors to 
genotoxic agents and ionizing radiation 45,46.  
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CHD3 and CHD4 are 69% identical and share a common domain structure 
including an n-terminal region, tandem PHD fingers, tandem chromo domains, an 
ATPase-helicase and c-terminal CHD domain (CTDCHD) or domains of unknown 
function (DUF) 47. The n-terminal region of CHD4 contains aHMG-box-like-domain 
which binds poly(ADP-ribose) in a poly(ADP-ribose) polymerase-dependent manner for 
recruitment to sites of DNA double-stranded breaks 48. Of the CHD4 tandem PHD 
fingers, PHD1 binds unmodified H3 tails and PHD2 binds H3 methylated at Lys9 and are 
required to recruit NuRD to target genes for transcriptional silencing 49. The chromo 
domains of the homologous CHD4 protein in Drosophila melanogaster are not essential 
for NuRD complex formation but have demonstrated the ability to bind DNA and 
stimulate ATPase activity of the helicase domain 50. The helicase alone is sufficient to 
bind nucleosomes and hydrolyze ATP, and the ability to slide mononucleosomes is 
enhanced in the presence of the PHD fingers and chromo domains 51. Truncations that 
interrupt the CHDCTD domain were shown to disrupt repression or reporter gene 
expression without changing CHD4 promoter occupation 52, however, the function of 
this domain has not been further explored. In Chapter 4, we discuss work that 
investigates the role of the CHDCTD domain in association with the NuRD complex. 
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Figure 3.1 NuRD Complex Subunit Domain Interaction Map 
The histone deacetylase core subcomplex (HDCC) of NuRD (highlighted in blue) forms 
through interfaces formed between the enzymatic domain of HDAC1/2 and the ELM2-
SANT domains (shown in red), c-terminal regions of MTA1/2 and RBBP4/7, as well as 
the interaction of HDAC1/2 and RBBP4/7. The HDCC associates with the IDR (green) 
of MBD2/3 which localizes the complex to methylated (red dots) or unmethylated CpG 
islands. GATAD2A/B is recruited to the complex through a coiled-coil interaction 
between the α-helix that comprises its CR1 domain and a c-terminal α-helix of MBD2 
(shown in cyan). CHD3/4 binds H3 n-terminal tails either unmodified or methylated at 
Lys9 via tandem PHD fingers and binds to DNA through the tandem chromodomains 
and helicase domain (shown in orange). Domains of unknown function in MTA2, 
GATAD2A, and CHD4 are shown in purple. 
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CHAPTER 4: CHARACTERIZATION OF NURD COMPLEX GATA-LIKE ZINC-
FINGER DOMAINS 
Characterization of GATAD2A-CHD4 Interaction Interface 
Studies of the interaction between the GATAD2A conserved region 1 (CR1) 
domain and the MBD2 coiled-coil revealed that a CR1 peptide was sufficient to 
immunoprecipitate NuRD components with the exclusion of CHD4 1. Additionally, 
reporter assays of CHD4 have demonstrated that the c-terminal CHDCTD domain is 
required for transcriptional silencing activity yet not required for gene promoter 
occupation 2. These observations led us to hypothesize that the conserved region 2 
(CR2) of GATAD2A might interact with CHD4, possibly through an interface with the 
CHDCTD domain. We report here findings demonstrate that CR2, specifically the 
GATA-like zinc-finger, is sufficient to immunoprecipitate CHD4 to the exclusion of other 
NuRD components. 
Materials and Methods 
Cloning, Expression, and Purification of the GATAD2A Zinc-Finger Domain 
GATAD2A CR2short (339-464 aa) and zinc-finger short (411-464 aa) constructs 
were cloned into the bacterial expression vector pGEX4T-1 (GE Healthcare 
Biosciences), which was engineered for the expression of recombinant proteins with an 
N-terminal tandem fusion tag of glutathione S-transferase (GST). The resulting GST-
GATAD2A fusions were overexpressed in the Rosetta II (DE3) (Invitrogen) E. coli strain 
and grown in Luria Bertani (LB) medium containing 50 μg/ml of ampicillin to an optical 
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density of 0.5 -0.6 at 600 nm, and then induced with 0.2 mM isopropyl-β-D-
thiogalactopyranooside for 2 h at 37 °C. Cells were harvested by centrifugation and 
lysed by sonication in 30 ml of the B-PER reagent (Thermo Scientific) supplemented 
with EDTA-free protease inhibitor tablets (Thermo Scientific). The fusion protein was 
isolated from the soluble fraction by GST affinity chromatography (GSTrap FF, GE 
Healthcare) and eluted with reduced glutathione buffer (25 mM glutathione, 50 mM Tris 
pH 8.8, 200 mM NaCl). 
Fluorescent Polarization DNA Binding Studies  
  5’-end 6-FAM labeled DNA oligos were ordered from Integrated DNA 
Technologies, and annealed and HPLC purified. Oligos and protein were each buffer 
exchanged into sample buffer [10mM HEPES (pH 7.5), 50 mM NaCl, 3 mM MgCl2, 0.1 
mM EDTA, 2 mM DTT]. The protein and DNA concentrations were measured by UV 
absorbance and diluted to 5 uM and 70 nM, respectively, in assay buffer [10mM HEPES 
(pH 7.5), 50 mM NaCl, 3 mM MgCl2, 0.1 mM EDTA, 2 mM DTT, 0.005% TWEEN 20].  
In a black, flat bottom, half volume 96 well plate (COSTAR), protein was serially diluted 
1:2 across each row, except for the protein-free control wells. DNA was added to a final 
concentration of 10 nM in every well, and samples in each row were mixed with a multi-
channel pipette. The protein-DNA complexes were incubated for 10 minutes at room 
temperature and then crosslinked with glutaraldehyde of varying concentrations and 
incubation times. Plates were read on a CLARIOstar plate reader (BMG Labtech), by 
focus adjusting on a protein-free control well and measuring fluorescent anisotropy at 
495 nm. 
Mammalian Cell Culture 
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Human embryonic kidney 293T (HEK293T) cells were maintained in Dulbecco’s 
modified Eagle’s Medium (DMEM) containing 10% heat-inactivated fetal bovine serum 
(Hyclone), 2mM L-glutamine and 100 U/ml penicillin and streptomycin. Cells were 
cultured at 37◦C and 5% CO2. 
Co-Immunoprecipitation 
GATAD2A constructs were cloned into the pCMV-Tag2b (Stratagene) vector in 
frame with an N-terminal flag-tag sequence. Plasmids were transfected into HEK293T 
cells with Turbofect according to the protocol for adherent cells (Thermo Scientific). At 
48 h post transfection, HEK293T cells were scraped off of plates in ice-cold 1x PBS, 
centrifuged at 250 x g for 5 minutes and resuspended in ice cold micrococcal nuclease 
(MNase) digestion buffer (25 mM HEPES-KOH pH 7.6, 100 mM NaCl, 5 mM MgCl2, 3 
mM CaCl2, 10 % glycerol, 0.2 % NP-40 and 1x EDTA-free protease inhibitor cocktail 
(Roche)). Cell pellets were lysed on ice with a pistol tissue homogenizer followed by 
MNase digestion using 1500 U/ml of MNase (Worthington Biochemical, Lakewood, NJ, 
USA) for 2 h on ice. Ethidium bromide was then added to the lysate at 300 μg/ml 
followed by a spin at 10,000 x g for 15 mins at 4 °C. The supernatant was then pre-
cleared by rotating with Protein G agarose beads (Thermo Scientific) for 2 hours at 
4 °C. Beads were removed by centrifugation at 5,000 x g for 30 seconds at 4 °C and 
supernatant were split into two fractions, one each incubated with anti-flag M2 antibody 
(Sigma F1804) or a mouse IgG (Santa Cruz) control, rotating overnight at 4 °C. Protein 
complexes were precipitated with Protein G agarose beads (Thermo Scientific) rotating 
for 3 h at 4 °C. Beads were washed with ice cold high salt buffer (1x PBS, 300 mM 
NaCl) four times before elution by boiling in laemmli sample buffer.  
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Western Blot Analysis 
Eluted immunoprecipitated proteins were analyzed for different components of 
the NuRD complex by western blot. Fractions were loaded in a pre-cast 4-20% gradient 
SDS-PAGE gels (Bio-Rad) and run at 120V for 60-90 minutes. Proteins were 
transferred to a 0.2 μm PVDF membrane activated in 100 % methanol running at 120V 
for 2 h in transfer buffer (25 mM Tris pH 8.5, 192 mM glycine, 10% methanol). 
Membranes were rinsed in 1x PBST and blocked at room temperature in 5% w/v nonfat 
dry milk for 30 minutes. Blots were probed with primary antibodies against RBBP4 
(Novus NBP1-40622), HDAC2 (Millipore 05–814), MTA2 (Santa Cruz sc-28731), MBD2 
(Santa Cruz sc-12444), CHD4 (Millipore 06–1306) and HRP-conjugated TrueBlot 
secondary antibodies (Rockland). After each antibody exposure blots were rinsed with 
1x PBST three times for 15 minutes. Blots were incubated in Luminata Crescendo 
Western HRP substrate (Millipore) and visualized by CCD imaging (ImageQuant LAS 
4000, GE Healthcare Biosciences). 
Cloning and Co-expression of the GATAD2A Zinc-Finger  
The GATAD2A zinc-finger (400-480 aa) was cloned into the pETDuet vector with 
an n-terminal 6xHis-tag and constructs of the c-terminal domains of CHD4 (1530-1912 
aa, 1686-1912 aa) were cloned into the second site of bicistronic pETDuet vector and 
the bacterial co-expression vector pCDF. Co-expression tests were conducted with 
Rosetta II (DE3) (Invitrogen) E. coli strain grown in Luria Bertani (LB) medium 
containing 50 μg/ml of ampicillin and/or kanamycin to an optical density of 0.6 at 600 
nm. Protein expression was induced with 1 mM IPTG and temperature conditions were 
varied (2 h at 37 °C, 4 h at 32 °C, or overnight at 23 °C and 16 °C). Cells were lysed in 
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B-PER reagent, the supernatant was removed and a portion of the membrane fraction 
was solubilized in 6M Urea. Samples of the soluble and insoluble fractions were boiled 
in laemmli sample buffer and analyzed by SDS-PAGE. 
Sequence Alignments 
 Amino acid sequences of GATAD2A CR2 and CDH4 CHDCTD were queried 
NCBI BLASTp to identify homologs in Amphimedon queenslandica and Hydra vulgaris. 
Clustal Omega of the analogous domains was used to generate a multiple sequence 
alignment (MSA). Sequence conservation was visualized with the Color Align 
Conservation tool of the Sequence Manipulation Suite 3. 
Results  
Conserved region 2 (CR2) of GATAD2A contains the GATA-like zinc-finger 
(GATAD2A ZnF) that gives the protein its name and is evolutionarily conserved in 
animals through sponges (Figure 4.1). From our published studies of the coiled-coil 
interaction between MBD2 and GATAD2A conserved region 1 (CR1), as mentioned in 
Chapter 3, we suspected that the CR2 domain was the critical interface for recruiting 
CHD4 to the NuRD complex. CR2, however, has also been previously implicated in 
binding chromatin and histone proteins 4.  To test this prior evidence, we purified a 
GST-tagged fusion of CR2 (Figure 4.2) that our collaborators in the Strahl lab screened 
for histone binding activity with an EPITITAN™ modified histone tail peptide array 
(EpiCypher), which yielded zero hits. We also ran a preliminary fluorescence 
polarization DNA binding assay, in the presence of the protein-DNA cross-linker 
glutaraldehyde, and did not detect a non-specific interaction with DNA (Figure 4.3).  
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To characterize the interaction of CR1 and CR2 with the NuRD complex, we 
performed immunoprecipitations with an n-terminal or c-terminal segment of GATAD2A 
and probed for the presence of RBBP4, HDAC2, MTA2, MBD2, and CHD4. We used 
ethidium bromide and a high salt wash to eliminate bridging interactions through the 
DNA binding domains of the complex. We confirmed our past finding that CR1 (1- 178 
aa) associates with RBBP4, HDAC2, MTA2, MBD2 but not CHD4. We also discovered 
that the c-terminal segment including CR2 (339-633 aa) associated with CHD4 but not 
any of the other probed NuRD complex components (Figure 4.4A). Subsequent 
immunoprecipitations identified that CR2 alone (339-480 aa), specifically the sequence 
encoding the predicted GATAD2A ZnF (400-480 aa), was sufficient to associate with 
CHD4 (Figure 4.5).  
We hypothesized that the c-terminal domain of CHD4, also known as the 
CHDCTD, would be the critical region for interacting with GATAD2A.  This region is 
conserved in animals through sponges (Figure 4.6) and recent proteomic studies of the 
human NuRD complex identified crosslinks between GATAD2A CR2 and amino acids in 
the CHDCTD region of CHD4 5. Our collaborators in the Mackay group determined that 
GATAD2B interacts with the second half of the CHDCTD domain amino acids 1686-
1912, which we refer to as C2 (Figure 4.4B and data not shown).  
We were interested in further characterizing the interaction of CHD4 and the 
GATAD2A ZnF in isolation, therefore, we attempted several approaches for bacterial 
expression. Initial experiments with cleaving the purified GATAD2A ZnF from the GST-
tag resulted in protein precipitation. Additionally, we suspected that the terminal helix of 
the zinc-finger (464-480 aa) might be involved in the interface, therefore we sought 
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strategies to express a larger construct. The fusion of a GST-tag to the full GATAD2A 
ZnF (400-480 aa) and expressing C2 independently both yielded only insoluble protein. 
We hypothesized that the interaction of the c-terminal region of CHD4 with the 
GATAD2A ZnF could stabilize both domains and we cloned segments into a bicistronic 
petDuet vector. By Coomassie staining, we detected bands in the insoluble fraction for 
CR2 and possibly in the soluble fraction for the full-length CHDCTD domain (Figure 
4.7). Efforts to optimize the dual expression system did not achieve improved results, 
therefore, we moved to a two-plasmid approach. A 6xHis-zinc-finger fusion and isolated 
C2 sequence were cloned into compatible expression vectors, co-transformed and 
subjected to double antibiotic selection. Test growths indicated that expression at 23 °C 
overnight is the optimal condition for obtaining both protein products in the soluble 
fraction (data not shown).   
Discussion and Future Directions 
The presented results suggest that CHD4 may be recruited to the NuRD complex 
through an interaction between the CHDCTD domain and the CR2 domain of 
GATAD2A. We propose that a function of GATAD2A in the NuRD complex is to serve 
as the bridge between the two enzymatic components, the HDCC and CHD4 (Figure 
4.8A). The zinc-finger domain of GATAD2A may contribute to the localization of CHD4 
at methylated CpG-islands through the CR1 domain interaction with MBD2 (Figure 
4.8B). In fact, previous studies have shown that early termination of the CHD4 transcript 
at 1840 aa disrupts foci in the nucleus 2. Future experiments aim to confirm the direct 
binding of the GATAD2A ZnF and the C2 region of CHD4 by demonstrating co-
purification. If bacterial protein production is insufficient to detect the interaction, 
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bioluminescence resonance energy transfer (BRET) with NanoLuc- and Halotag- fusion 
proteins may prove useful to test in cell proximity 6. Disrupting BRET by removing the 
characteristic cysteines or the predicted c-terminal helix of the zinc-finger domain would 
provide further evidence of an interaction and identify the pertinent structures. 
Clarification of the minimal binding region through experiments with truncated 
constructs could also reveal a complex more amenable to co-expression and ultimately 
crystallization of the protein complex to elucidate the atomic-level details of the 
interaction.  
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Amphimedon IKAKEKQGSADTSLKCPTCDTSVNLPDGK----------------------IEGLTQNLW-FEHKSKEA 
HUMAN      ESPASRQAAAKLALRKQLEKTLLEIPPPKPPAPEMNFLPSAANNEFIYLVGLEEVVQNLLETQGRMS-- 
Hydra      ISAEQKQNAAKTALHRQLEQTLLQIPPPRPPPADWKAIPNVNSMDFMMLVGLDEVVDSILEMDSKPTIK 
 
Amphimedon SIKKKIHSREPILCGKCRVKDSSDAAVVYCCDCGKFLCEYCKNGHKRNPEKADHELIDLGEAARKALKE 
HUMAN      --AATVLSREPYMCAQCKTDFTCRWR--EEK-SGAIMCENCMTTNQKKALKVEHTSR-LKAAFVKALQQ 
Hydra      KALAELIPYNPRVCNQCNVDFSPCWK--SKDGEDFVLCERCALQNIKRDLKAEHTKR-LKDAFLKALTQ 
 
Amphimedon SVTSCDGVIPPVTEAIANGE  
HUMAN      EQE--------IEQRLLQQG 
Hydra      EQE--------IEERIKAGE 
 
Figure 4.1 Evolutionary conservation of GATAD2A CR2 sequence 
Alignment of human GATAD2A amino acids 339-480 with orthologous proteins from 
early eukaryotes Amphimedon queenslandica and Hydra vulgaris. Identical residues are 
highlighted in black and similar residues are shaded in gray. 
 
 
 
 
 
 
  
Figure 4.2 GST-fusion GATAD2A CR2 purification 
Coomassie-stained SDS-PAGE gel of the flow-through (FT) and elution fractions from a 
GSTrap FF column extracting the GST-CR2 fusion protein (expected molecular weight 
33 kDa). 
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Figure 4.3 GATAD2A CR2 did not exhibit non-specific DNA binding activity 
Plotted polarized fluorescence units (FU) detected with an increasing micromolar (μM) 
concentration of GST-CR2 protein at varying concentrations of glutaraldehyde 
crosslinking reagent. 
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 Figure 4.4 GATAD2A bridges the enzymatic components of the NuRD complex 
A) The N-terminal half of GATAD2A interacts with most canonical NuRD components 
except CHD4 while C-terminal half interacts with CHD4. B) Likewise, 
immunoprecipitating the C-terminus of CHD4 is sufficient to detect GATAD2B. 
 
 Figure 4.5 Zinc-finger domain of GATAD2A associates with CHD4 
Removal of the amino acids c-terminal and n-terminal of the zinc-finger domain in the 
339-480 aa and 400-480 aa constructs does not disrupt binding to CHD4. In the 
absence of the zinc-finger, the CR2 residues 339-400 do not pull down CHD4. 
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 Figure 4.6 Evolutionary conservation of CHD4 C2 sequence 
Alignment of human CHD4 amino acids 1686-1912 with orthologous proteins from early 
eukaryotes Amphimedon queenslandica and Hydra vulgaris. Identical residues are 
highlighted in black and similar residues are shaded in gray. 
  
Figure 4.7 GATAD2A CR2 and CHD4 co-expression 
Coomassie-stained SDS-PAGE gel of the insoluble (pellet) and soluble (supe) fractions 
of whole cell lysates after expressing CR2 and c-terminal CHD4 (C1-C2) constructs 
from the same bicistronic petDuet vector. Expected molecular weights are 17 kDa 
(CR2) and 80 kDa (CHD4). 
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Figure 4.8 Models of CHD4 Recruitment to NuRD 
A) GATAD2A bridges the histone deacetylase and nucleosome remodeling activities of 
NuRD associating with the HDCC through the CR1 interaction with MBD2 and with 
CHD4 through an interaction with the zinc-finger of CR2.  
B) The zinc-finger domain of GATAD2A may contribute to the localization of CHD4 at 
methylated CpG-islands through the CR1 domain interaction with MBD2. 
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Functional Characterization of MTA2 Zinc Finger Domain  
Zinc-fingers are classically considered nucleic acid binding domains 7–11, 
however, many have also been found to be protein-protein interaction domains 12–14, 
including histone modification readers 15,16. MTA2 is a component of the histone 
deacetylase core complex (HDCC) which we have shown interacts with the NuRD 
complex through contact with the MBD2 intrinsically disordered region (IDR). Residues 
of the MBD2 IDR critical to the HDCC complex interaction were identified, however, the 
identity of HDCC domains involved in the interface remain elusive 17. The zinc-finger 
domain (ZnF) of MTA2 has not been functionally characterized, therefore we sought to 
examine its possible function as a domain for interaction with the MBD2 IDR, histone 
tails, and DNA. Here, we present findings that suggest the MTA2 ZnF in isolation does 
not associate with the MBD2 IDR, unmodified or modified histone tail peptides, and may 
have non-specific DNA binding activity. 
Materials and Methods 
Cloning, Expression, and Purification of the MTA2 Zinc-Finger Domain 
The MTA2 zinc-finger (178-255 aa) was cloned into the bacterial expression 
vector pGEX4T-1 (GE Healthcare Biosciences), which was engineered for the 
expression of recombinant proteins with an N-terminal tandem fusion tag of glutathione 
S-transferase (GST). The resulting GST-MTA2 fusion was overexpressed in the Rosetta 
II (DE3) (Invitrogen) E. coli strain and grown in Luria Bertani (LB) medium containing 50 
μg/ml of ampicillin to an optical density of 0.5 -0.6 at 600 nm, and then induced with 0.2 
mM isopropyl-β-D-thiogalactopyranooside for 2 h at 37 °C. Cells were harvested by 
centrifugation and lysed by sonication in 30 ml of the B-PER reagent (Thermo Scientific) 
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supplemented with EDTA-free protease inhibitor tablets (Thermo Scientific). The fusion 
protein was isolated from the soluble fraction by GST affinity chromatography (GSTrap 
FF, GE Healthcare) and eluted with reduced glutathione buffer (25 mM glutathione, 50 
mM Tris pH 8.8, 200 mM NaCl). 
Fluorescent Polarization DNA Binding Studies  
  5’-end 6-FAM labeled DNA oligos were ordered from Integrated DNA 
Technologies, and annealed and HPLC purified. Oligos and protein were each buffer 
exchanged into sample buffer [10mM HEPES (pH 7.5), 50 mM NaCl, 3 mM MgCl2, 0.1 
mM EDTA, 2 mM DTT]. The protein and DNA concentrations were measured by UV 
absorbance and diluted to 5 uM and 70 nM, respectively, in assay buffer [10mM HEPES 
(pH 7.5), 50 mM NaCl, 3 mM MgCl2, 0.1 mM EDTA, 2 mM DTT, 0.005% TWEEN 20].  
In a black, flat bottom, half volume 96 well plate (COSTAR), protein was serially diluted 
1:2 across each row, except for the protein-free control wells. DNA was added to a final 
concentration of 10 nM in every well, and samples in each row were mixed with a multi-
channel pipette. The protein-DNA complexes were incubated for 10 minutes at room 
temperature and then crosslinked with glutaraldehyde of varying concentrations and 
incubation times. Plates were read on a CLARIOstar plate reader (BMG Labtech), by 
focus adjusting on a protein-free control well and measuring fluorescent anisotropy at 
495 nm. 
NMR Binding Experiments  
GST-MTA2 fusion protein (GST-MTA2_ZnF) was overexpressed in the Rosetta II 
(DE3) (Invitrogen) E. coli strain and grown in minimal (M9) media supplemented with 
15N ammonium chloride and containing 50 μg/ml of ampicillin. Cells were grown to an 
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optical density of 0.5 -0.6 at 600 nm and then induced with 0.2 mM isopropyl-β-D-
thiogalactopyranooside for 4 h at 37 °C. Cells were harvested by centrifugation and 
lysed by sonication in 30 ml of the B-PER reagent (Thermo Scientific) supplemented 
with EDTA-free protease inhibitor tablets (Thermo Scientific). The fusion protein was 
isolated from the soluble fraction by GST affinity chromatography (GSTrap FF, GE 
Healthcare) and eluted with reduced glutathione buffer (25 mM glutathione, 50 mM Tris 
pH 8.8, 200 mM NaCl). The GST-tag was removed by thrombin cleavage overnight at 
4 °C. Thrombin was removed by gravity affinity chromatography with a benzamidine 
sepharose resin (Thermo Scientific) and MTA2 ZnF protein was isolated via gel filtration 
chromatography with a Superdex 75 10/300 GL column (GE Healthcare). Fractions 
containing MTA2 ZnF protein were further purified via ion exchange chromatography 
over a Source 15S 4.6/100 column (GE Healthcare), then combined and buffer 
exchanged into NMR buffer [10 mM sodium phosphate pH 6.5, 10% D2O]. Final protein 
concentration was determined by UV absorption at 280 nm. 
Seventeen base pair oligonucleotides (forward: GAGGCGCTCGGCGGCAG; 
reverse: CTGCCGCCGAGCGCCTC) were purchased (IDT Technologies), annealed, 
and purified by ion exchange chromatography over a Source 15Q 4.6/100 column (GE 
Healthcare). Fractions containing double-stranded DNA were then combined and buffer 
exchanged into NMR buffer. Final DNA concentration was determined by UV absorption 
at 260 nm. One, two and three molar equivalents of DNA were titrated into a 200 µM 15N 
labeled MTA2 ZnF protein sample in NMR buffer.  
15N labeled MBD2 intrinsically disordered region (IDR) protein was expressed 
and purified as previously described 1>. One or two molar equivalents of unlabeled 
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MTA2 ZnF protein in NMR Buffer was added to the 15N labeled MBD2 IDR sample. 
HSQC spectra were collected at 25°C with a Bruker Avance III NMR spectrometer 
equipped with a cryogenic probe and operated at a 1H frequency of 700 MHz.  
Results  
We purified a GST-tagged fusion of MTA2 zinc-finger (GST-MTA2_ZnF) (Figure 
4.1) that our collaborators in the Strahl lab screened for histone binding activity with an 
EPITITAN™ modified histone tail peptide array (EpiCypher), which yielded zero hits. 
We also ran a preliminary fluorescence polarization DNA binding assay, in the presence 
of the protein-DNA cross-linker glutaraldehyde, and did not detect a non-specific 
interaction with DNA (Figure 4.2). To test for interaction with the intrinsically disordered 
region (IDR) of MBD2 we ran HSQC titration experiments with 15N labeled MBD2 IDR 
and unlabeled MTA2 ZnF protein. The MBD2 IDR alone has a distinct pattern of 
chemical shifts concentrated between 7.5 and 8.75 ppm in the 1H dimension, seen in 
the left panel of Figure 4.3. The chemical shifts did not change in the presence of 
increasing concentrations of MTA2 ZnF protein, demonstrated by the overlying blue and 
green spectra in the right panel of Figure 4.3. An additional HSQC experiment was 
conducted with 15N labeled MTA2 ZnF protein in the presence of increasing 
concentration of double stranded DNA. Data could not be collected on the samples, 
however, as the addition of one, two or three molar equivalent of DNA immediately 
formed a white precipitate and signal was no longer obtainable from the NMR sample 
over the noise. Increasing the salt concentration did not prevent precipitate formation 
(data not shown).  
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Discussion and Future Directions 
The absence of hits from the modified histone tail peptide array and the lack of 
observable chemical shift perturbations in the MBD2 IDR spectrum upon exposure to 
the MTA2 ZnF protein leads us to conclude that they do not likely interact within the 
NuRD complex. It is possible that larger interaction interfaces are required to observe 
the MTA2 ZnF contribution to the interaction of the histone deacetylase core complex 
(HDCC) with MBD2 or histones, and future experiments could be designed to test this. 
Co-expression and purification of HDAC, RBBP4/8, and MTA constructs with and 
without the zinc-finger domain would allow for further examination of the role of the 
MTA2 ZnF in complex formation by testing the interaction with MBD2 full-length protein 
and IDR domain. Such interactions could be examined with analytical size exclusion 
chromatography, light scattering, in vitro pull-downs or HSQC titration experiments. 
Taking measurements of binding affinity with histone proteins or assembled 
nucleosomes may also inform if the MTA2 ZnF measurably adds to the association of 
the HDCC with chromatin. 
Alternatively, the precipitation of MTA2 ZnF protein in the presence of equal and 
excess concentrations of double-stranded DNA might indicate non-specific DNA binding 
and this possibility should also be further explored. Sequence specificity could be 
examined with SELEX experiments or DNA footprinting assays focused on sequences 
near loci thought to be regulated by the NuRD complex. Enriched sequences should 
then be confirmed and characterized by biochemical or biophysical techniques, such as 
electromobility shift assay (EMSA), fluorescence polarization, isothermal calorimetry or 
 
 122
HSQC titration experiments, towards ultimately solving a solution NMR structure of a 
relevant complex.   
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Figure 4.9 GST-fusion MTA2 zinc-finger purification 
Coomassie-stained SDS-PAGE gel of the insoluble (pellet) and soluble (lysate) fractions 
of bacterial whole cell lysates following expression of the GST-tagged MTA2 zinc-finger 
(GST-MTA2_ZnF) domain. Subsequent lanes include the flow-through (FT) and elution 
fractions from a GSTrap FF column extracting the GST-MTA2 fusion protein (expected 
molecular weight 35 kDa). 
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Figure 4.10 MTA2 zinc-finger did not exhibit DNA binding activity by fluorescence 
polarization  
Plotted polarized fluorescence units (FU) detected with an increasing micromolar (μM) 
concentration of GST-MTA2_ZnF protein at varying concentrations of glutaraldehyde 
crosslinking reagent. 
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Figure 4.11 MTA2 zinc-finger did not exhibit binding to the MBD2 IDR via HSQC 
HSQC spectra of 15N labeled MBD2 intrinsically disordered region (IRD) protein free in 
solution (red). The left panel displays overlaid spectra of the IDR incubated with one 
(blue) or two (green) molar equivalents of unlabeled MTA2 ZnF protein. 
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